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Malaria is a global health crisis that threatens almost half of the 
world’s population. The need for novel antimalarials is becoming 
increasingly urgent as the incidence of resistance rises against the first-
line defense, artemisinin. Plasmodium falciparum, the causative agent of 
the most lethal form of malaria, is a member of the phylum Apicomplexa. 
This phylum of parasitic protists is responsible for a number of diseases 
afflicting both human and non-human hosts, resulting in significant 
health and economic burdens worldwide. Recent work has pointed to the 
conserved autophagy pathway within these parasites as a potential target 
for anti-apicomplexan drug development. 
In this body of work, two approaches are taken to identify novel 
small molecules targeting the autophagy pathways within Plasmodium, 
and within other apicomplexans, as well. 
The first approach involves a Virtual Ligand Screen of the 
ChemBridgeTM Express Library against the crystal structure of P. 
falciparum Atg8. Hits are ordered and tested using SPR to detect activity 
against the plasmodial interaction without targeting the human 
interaction. The top hit, ALC25, is verified in vitro using SPR dose 
dependency, thermal shift, and ITC; it is additionally confirmed in vivo 
against both blood- and liver-stage P. falciparum parasites. ALC25 
exhibits modest antimalarial activity, with IC50 values below 20 µM. 
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The second approach expands upon hits identified from the 
Medicines for Malaria Venture (MMV) Malaria Box. These hits were 
detected via a medium-throughput Surface Plasmon Resonance (SPR) 
interaction assay and were subsequently verified in vivo. The small 
molecule scaffold for these hits is then chemically diversified and tested, 
again using SPR, against the Atg8-Atg3 interactions from Plasmodium 
falciparum, Cryptosporidium parvum, Eimeria tenella, and Neospora 
caninum/T.gondii, with promising results. 
These compounds, targeting the Atg8 conjugation pathway within 
P. falciparum, are then used to begin exploring the novel connection 
between the plasmodial autophagy pathway and the export of P. 
falciparum Erythrocitic Membrane Protein 1 (PfEMP1), a connection with 
profound implications for the potential treatment of cerebral malaria.  
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Autophagy is an important metabolic pathway, conserved within 
eukaryotes, for the degradation of superfluous or damaged proteins and 
organelles. In addition to its role in homeostasis and survival under 
starvation conditions, autophagy has been found to function in a variety 
of pathways including cell differentiation and development, cell-mediated 
death, and clearance of intracellular pathogens. Within the phylum 
Apicomplexa, however, autophagy has increasingly been found to serve 
novel roles specific to intracellular parasite biology. Apicomplexa are 
obligate intracellular parasitic protists that represent a significant global 
burden to human health and economic development. Autophagy within 
these parasites represents an attractive target for novel anti-
apicomplexan therapies. Here, recent advances in the field of 
apicomplexan autophagy research are presented. We also discuss recent 
results from our laboratory, in which we use two different approaches to 
identify novel lead-like molecules that inhibit the PfAtg3-PfAtg8 protein–
protein interaction. These compounds have activity against blood and 
liver stage Plasmodium falciparum malaria and lead to an upregulation 
and shift in lipidation state of PfAtg8. The molecules and methods 
identified from these two complementary approaches have applications 
for apicomplexan small-molecule intervention strategies in general. 
  
 3 
Relevance and introduction to thesis 
For a disease like malaria, eradication cannot be realized from a 
single approach. Recent years have seen a mounting emphasis on 
prevention, in the form of insecticide-treated nets and indoor residual 
spraying [1], and vaccine development [2]. These approaches offer 
significant appeal. Anti-vector techniques alone are estimated to have 
prevented more than 500 million cases in the period between 2000 and 
2015 [3], and the RTS,S/AS01 malaria vaccine has been shown to have 
some limited efficacy in the broader population: 36 percent vaccine 
efficacy against clinical malaria when administered in three doses with 
an additional booster [4]. However, the RTS,S/AS01 malaria vaccine 
presents no significant protection against severe malaria; in fact, without 
the booster dose, it may contribute to cases of severe malaria by 
preventing the natural progression of immunity [4]. 
More generally, neither preventative measures nor current vaccines 
offer solutions for the millions of people who will become sick every year 
at the hands of this disease. Not only does this represent a substantial 
burden of human suffering, but it also influences the achievability of any 
plan for malaria elimination: these individuals represent an ever-present 
pool of disease carriers. As long as prevention and vaccination remain 
imperfect, malaria will continue to wreak havoc on the human 
population in the absence of effective medication. Thus, for the sake of 
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human health in the moment and eradication in the long run, drug 
development must also play a role. 
For those who suffer from this illness, current treatment options 
are frighteningly limited. With chloroquine resistance nearly universal, 
artemisinin-based combination therapies (ACTs) are the go to treatment. 
Now, however, even ACTs have been threatened as reliable treatment 
options: resistance has been detected in at least five countries and is 
spreading over time [5]. As we deal with mounting resistance to ACT, new 
antimalarials are desperately needed. 
This urgent need forms the foundation for this body of work. My 
doctoral research focuses on the search for antimalarials targeting the 
Plasmodium falciparum autophagy system. In the first chapter, I discuss 
the current understanding of autophagy within the phylum Apicomplexa, 
of which Plasmodium is a member, and briefly discuss two approaches 
we have taken to target the plasmodial autophagy system. In the second 
chapter, I detail a Virtual Ligand Screening approach to drug discovery. 
In the third chapter, I present the results of further testing of the PTA 
derivative molecules previously found to inhibit an important autophagic 
protein-protein interaction in P. falciparum. Finally, chapter four 





Autophagy: an overview 
Macroautophagy, or more simply autophagy, is a catabolic process 
within eukaryotic cells responsible for the recycling of intracellular 
material. It is mediated by double-membrane-bound vesicles called 
autophagosomes, which engulf cytoplasmic material and organelles 
before fusing with the lysosome to form autolysosomes [6]. This process 
is widely conserved in eukaryotes [7] and is involved in a variety of 
functions within the cell. Autophagy facilitates cellular homeostasis, 
occurring constitutively at a basal level to regularly turn over damaged or 
unused cellular debris and organelles [8,9]. Under amino acid starvation 
conditions, autophagy is significantly upregulated in order to internally 
scavenge the materials necessary for continued survival [10]. In addition 
to functioning in homeostasis and the stress response [11,12], autophagy 
is also involved in a variety of other cellular processes. For example, 
autophagy serves an important role in cell differentiation and 
development, where it facilitates rapid changes in the cellular 
environment through degradation of unnecessary intracellular structures 
and organelles [13]. As a natural extension of its role in engulfing 
unwanted intracellular components, autophagy is also involved in the 
clearance of intracellular pathogens through a process termed xenophagy 
[14]. Finally, in a seeming contradiction to its role in cell survival under 
amino acid starvation conditions, autophagy also appears to be involved 
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in non-apoptotic programmed cell death under specific cellular 
conditions [15]. 
This complex range of functions is performed by a set of more than 
30 autophagy (Atg) proteins that have been well-characterized in yeast 
[16]. It is useful to have an overview of the main proteins and complexes 
involved in performing macroautophagy within yeast before taking a 
closer look at autophagy within Apicomplexa [17] (Figure 1.1A). 
Initiation, the first step in autophagy, begins when the Atg1 initiation 
complex forms at the Pre-Autophagosomal Structure (PAS), the site from 
which the autophagosome originates [18]. The formation of the Atg1 
complex is controlled by negative regulation through Target Of 
Rapamycin Complex 1 (TORC1), the inhibitory function of which can be 
blocked by exposure to amino acid starvation conditions or treatment 
with rapamycin [19]. The Atg1 complex consists of the kinases Atg1 and 
Atg13, which bind to the ternary complex formed by Atg17 bound to 
Atg31 and Atg29 [20]. Once formed, the Atg1 complex activates the class 
III phosphatidyl-inositol 3-phosphate kinase (PI3K) complex (comprising: 
Vps34, Vps15, Vps30/Atg6, Atg14, and Atg38) [21,22]. The activated 
PI3K class III complex initiates phagophore assembly, converting 
phosphatidylinositol (PI) into phosphatidylinositol triphosphate (PI3P) at 
the PAS. Wortmannin and 3-methyladenine, classic autophagy 
inhibitors, inhibit PI3K activity [23]. The existence of PI3P at the PAS 
then recruits several autophagy-related proteins (Atg2, Atg9, and Atg18) 
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to bind to the incipient phagophore [24]. Although its role remains 
somewhat unclear, Atg9 is thought to transport membrane to the 
phagophore at this stage [25]. Elongation and closure of the phagophore, 
to form a completed autophagosome, require conjugation of Atg8’s C-
terminal exposed glycine residue to phosphatidylethanolamine (PE) 
within the phagophore membrane [26]. 
Atg8 is a ubiquitin-like protein (Ubl) whose conjugation pathway 
involves the enzymatic function of several Atg proteins. Atg4 is a protease 
that cleaves the C-terminal tail of Atg8, exposing a conserved glycine 
residue necessary for Atg8 conjugation with PE; Atg4 also functions to 
deconjugate Atg8 from the autophagosomal membrane [27]. Atg7 is an 
E1-activating enzyme; Atg3 is the E2-conjugating enzyme actually 
responsible for conjugating Atg8 to PE via Atg8’s exposed C-terminal 
glycine; and the covalently bound Atg12–Atg5 proteins form a complex 
with Atg16 to significantly increase Atg8 conjugation, by acting as an E3-
like enzyme [28–30]. Atg12 is also a Ubl, requiring the same E1 enzyme, 
Atg7, and its own E2 enzyme, Atg10, to covalently attach it to Atg5 [28]. 
Once Atg8 has been conjugated to the membrane, the phagophore 
elongates, engulfing the intracellular material, and then closes before 
fusing with the lysosome. 
Autophagy is increasingly appreciated for its roles, not only within 
healthy cells but also within diseased or infected cells, where, in many 
cases, it is shown to have both pro- and anti-survival effects, depending 
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on the specific cellular environment. For all of these reasons, research 
into this process is essential for developing our understanding of 
fundamental cell function and disease progression. However, while this 
pathway continues to be well-explored within yeast and other higher 
eukaryotes, the situation is much less clear for protists, including those 
in the phylum Apicomplexa. 
 
Phylum, Apicomplexa 
Apicomplexa is a phylum of parasitic protists that represent a 
significant threat to human health and economic development. 
Plasmodium, the best known member of the phylum, is responsible for 
the disease malaria, which kills about 500,000 people every year 
(www.who.int/topics/malaria). While Plasmodium is undoubtedly the 
deadliest organism in the phylum, many other Apicomplexa present a 
significant threat to immunocompromised individuals or to the livestock 
industry. Toxoplasma gondii, the causative agent of toxoplasmosis, 
infects nearly one third of the world’s population [31]. While T. gondii 
infection is predominantly harmless in healthy individuals, 
toxoplasmosis can be deadly for HIV patients and pregnant women, 
whose unborn children can acquire severe health complications through 
congenital infection (www.cdc.gov/toxoplasmosis). Cryptosporidium 
parvum is another organism that threatens the immunocompromised 
through the disease cryptosporidiosis, one of the major causes of water-
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borne illness globally [32]. For the agricultural industry, there are several 
organisms of considerable concern. Neospora caninum, Babesia bovis, 
and Theileria annulata all affect the cattle industry; N. caninum is one of 
the primary causes of fetal death in cows [33]. Eimeria tenella afflicts the 
poultry industry, causing caecal coccidiosis in young poultry [34]. It is 
difficult to estimate the cost of these various infections to the livestock 
industry, though N. caninum alone is estimated to lead to losses of over 
half a billion dollars annually to the U.S. cattle industry [35]. Because of 
these economic losses, apicomplexan infections are not only a 
considerable threat to human health and wellbeing, but also a threat to 
the growth of developing nations due to the sheer burden of these 
diseases on a growing economy. 
While various anti-apicomplexan therapies are in use, not all are 
wholly effective or cost-effective. Of pressing concern is the need for novel 
antimalarials, as increasing reports of drug resistance have been 
emerging against artemisinin, the first line of defense [5,36]. To develop 
new classes of anti-apicomplexan therapies, it is essential to identify 
viable targets within these eukaryotic pathogens, targets with enough 
divergence from host systems to ensure specificity and limit off-target 
effects. 
In terms of their basic biology, Apicomplexa are characterized by 
several shared features. They are obligate intracellular parasites, with 
complex life cycles spanning multiple hosts. They are classified based on 
 10 
a conserved “apical complex,” a structure used for host cell invasion with 
specialized secretory organelles, including micronemes and rhoptries 
[37]. Most of the organisms (C. parvum is a notable exception) feature a 
unique plastid organelle called the apicoplast, which was acquired 
through secondary endosymbiosis, resulting in a structure bound by four 
membranes [38]. This organelle functions in the synthesis of fatty acids, 
isoprenoids, iron-sulfur clusters, and heme [38]. Added to the shared 
physical characteristics of Apicomplexa is the additional common feature 
of spending the majority of their life cycle within host cells. Because of 
this distinct cellular environment, Apicomplexa differ from other 
unicellular eukaryotes in a myriad of ways; this extends to the process of 
autophagy, as well. 
 
Conservation of autophagy in Apicomplexa 
Autophagy within Apicomplexa represents an important and 
growing area of research, not only as a method to better understand the 
biology of these parasites, but also as a potential target for future drug 
discovery efforts.  At this stage, the genomes for several parasites within 
this phylum are available, including those species listed above [39]. It is 
important to remember the level of diversity represented within a 
phylogenetic group, a point which is of particular relevance for 
Apicomplexa, as they have considerable intra-phylum genetic variation 
[40]. In spite of this level of diversity, it is still possible to obtain a general 
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sense for the degree of conservation of the autophagy proteins in the 
phylum. Based on a variety of genome analyses, homologues for a 
number of proteins have been identified [17,41–49]. The P. falciparum 
genome, in particular, has been subjected to numerous searches for Atg 
homologues. As the majority of homologues have been determined via 
computational rather than experimental analyses, there is a considerable 
amount of disagreement in the results of these investigations. From the 
aforementioned screens, various P. falciparum homologues have been 
proposed for the following: Atg1, Atg2, Atg3, Atg4, Atg5, Vps30/Atg6, 
Atg7, Atg8, Atg10, Atg12, Atg14, Atg15, Vps15, Atg16, Atg17, Atg18, 
Atg22, Vps34, and TOR [17,41–47,49]. For any single analysis, many 
fewer homologues were identified (e.g., Figure 1.1B). Similarly, for T. 
gondii, Atg1, Atg3, Atg4, Atg5, Vps30/Atg6, Atg7, Atg8, Atg9, Atg12, 
Vps15, Atg17, Atg18, Vps34, and TOR homologues have been presented 
[48,49]. Other Apicomplexa, including N. caninum, E. tenella, C. parvum, 
C. hominis, and Theileria spp. have also been investigated [41–43,48,49]. 
Given the range of results that have been reported, it is therefore 
noteworthy that the entire Atg8 conjugation pathway (Atg3, Atg4, Atg7, 
and Atg8) has consistently been found to be conserved in Apicomplexa. 
For this reason, the identified homologues have received special focus. 
From a number of studies, it appears that the pathway is not only 
conserved, but also essential to parasite survival. The crucial nature of 
the Atg8 conjugation pathway represents a point of divergence from other 
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eukaryotes, as it has been shown that many Atg protein knockout 
strains in yeast or mammalian organisms are still viable [13,26]. This 
essentiality has been demonstrated for three Atg proteins in T. gondii: 
interference with the Ubl TgAtg8 leads to non-viable parasites [50]; 
elimination of the protease TgAtg4 results in significant growth defects 
[50]; and the E2-like enzyme TgAtg3 is also essential for normal organelle 
morphology and intracellular development [48]. Similarly, in Plasmodium, 
PfAtg8 knockouts are nonviable [42,43] and PfAtg7 is essential for 
normal growth [47]. 
 
Functions of apicomplexan autophagy proteins 
From these studies, it is clear that Apicomplexa make use of, and 
require, a much more limited repertoire of autophagy proteins. But to 
what end? Are these organisms performing canonical autophagy, or is 
this more limited set of autophagy proteins serving different purposes 
altogether? A growing body of research has arisen to provide some 
answers to these questions. In particular, more information about the 
function of the Atg proteins within Toxoplasma and Plasmodium is now 
available, though significant questions still remain to be answered. 
Atg8 in yeast and other eukaryotes is synthesized with a C-
terminal extension that must be cleaved to expose the glycine residue 
necessary for conjugation to PE [51,52]. In Apicomplexa, however, Atg8 
homologues contain a glycine as the C-terminal residue, implying that 
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the protein does not need to be modified by proteolytic cleavage prior to 
conjugation to PE and, presumably, a membrane. This is true for 
potential homologues of Atg8 identified in B. bovis (EuPathDB gene id: 
BBOV_III005950), E. tenella (ETH_00016760), N. caninum 
(NCLIV_008410), Plasmodium spp. (e.g., PF3D7_1019900), T. annulata 
(TA12615), and T. gondii (TGME49_254120) [39]. C. parvum Atg8 
(cgd7_3990) is an exception [39]. Perhaps because it is already in this 
active form, Atg8 in both Plasmodium and Toxoplasma exists in a 
predominantly lipidated, membrane-associated form [46,53,54]. Although 
Atg8 does not need to be pre-processed by Atg4 in these parasites, Atg4 
is nevertheless essential to intracellular development in T. gondii, and a 
role in Atg8 recycling from the membrane was proposed, which appears 
to be essential for the parasites [27,50]. 
The observation that the majority of Atg8 in these organisms is 
membrane-bound leads to one of the most unequivocally established 
connections to autophagy made within Apicomplexa: in numerous 
studies on T. gondii and Plasmodium species, Atg8 has been found to 
partially or completely co-localize with the apicoplast membrane [55]. Its 
role in this location is unclear, though it appears that Atg8 is conjugated 
to PE in the outermost membrane of the organelle [45,50,56], and it is 
not engulfing the apicoplast within an autophagosome [45,53,54]. For 
these reasons, and because ablation of Atg4 function leads to significant 
defects in apicoplast morphology [50], Atg8 is thought to play a 
 14 
fundamental role in the biogenesis and maintenance of the apicoplast 
[45]. However, this is not the only function of the protein within the 
parasite. 
Apicomplexa undergo significant morphological changes over the 
course of their life cycle, changes which must be accompanied by rapid 
remodeling of the cellular environment with the creation and disposal of 
stage-specific organelles. As mentioned in the overview of autophagy in 
higher eukaryotes, autophagy plays a pivotal role in mammalian cell 
differentiation and development [13,57]; these results also apply to 
certain eukaryotic pathogens, including pathogenic strains of the fungus 
Candida [58,59]. More significantly, autophagy has also been implicated 
in the cellular differentiation and homeostasis of trypanosomatids [60], 
particularly Trypanosoma brucei [61], Trypanosoma cruzi [62,63], and 
Leishmania spp. [64–67], organisms which undergo similarly complex 
changes in morphology to adapt to diverse host cell environments. For 
these reasons, a role for autophagy in apicomplexan development and 
differentiation has been explored. There are clear indications of this in T. 
gondii, since, as mentioned above, TgAtg3 is essential to normal cellular 
development: loss of TgAtg3 led to significant morphological and growth 
defects. [48]. For P. falciparum, the parasite enters the human host as an 
elongated sporozoite, a highly motile and invasion-competent form of the 
parasite that penetrates a hepatocyte before transforming into a round, 
metabolically active trophozoite that then replicates [68]. This 
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metamorphosis is accompanied by reorganization of cytoskeletal 
structure and clearance of the rhoptries, micronemes, and inner 
membrane complex [69]. Autophagy has been proposed as one 
mechanism for this clearance. In support of this proposal, membranous 
structures enclosing micronemes have been detected via electron 
microscopy during this metamorphosis [69], and 3-MA delays conversion 
of sporozoites to trophozoites [70]. 
Further exploring this idea of autophagosomes being coopted for 
exophagy, there is some evidence to suggest that the autophagy pathway 
within Apicomplexa may serve a role in trafficking to the host cell. Both 
PfAtg8 and PfPI3K have been found near the Maurer’s cleft [71,72], a 
structure essential to vesicular traffic to the red blood cell (RBC) 
membrane [73]. This idea may be further supported by the existence of 
PfAtg8 punctate structures throughout the RBC [46], as these structures 
could be involved in the export necessary for extensive host cell 
remodeling, although these structures have also been proposed to serve 
other functions. However, the existence of Atg8 in these punctate 
structures and near the Maurer’s cleft remains a disputed finding, as 
several studies have found no evidence of PfAtg8 aside from its apicoplast 
association [53,54,56]. These contradictory results may arise from 
differences in protein constructs and detection methods. Either way, 
further investigation is clearly necessary to shed light on whether or not 
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PfAtg8 is in fact exported to the host cell, and, if so, what its function 
may be there.  
The apicomplexan response to amino acid starvation is an area of 
some debate, as various studies have pointed to parasites engaging in a 
variety of responses, including hibernation, autophagosomal scavenging, 
or autophagic programmed cell death. This is not unexpected: as 
mentioned earlier for other eukaryotes, autophagy often plays a role in 
both pro-survival and pro-death functions. Indications of a pro-survival 
role arise in response to starvation conditions within the cell. In 
particular, nutrient or amino acid deprivation in both T. gondii [48,74] 
and P. falciparum [45,75] parasites led to PfAtg8 punctate structures 
throughout the cell. In P. falciparum, PfAtg8 was found to co-localize with 
PfRAB7 upon amino acid starvation, the plasmodial homologue of RAB7, 
an important protein in autolysosomal formation in higher eukaryotes 
[45]. Notably, these proteins were also detected in association with the 
food vacuole [45]. However, not every study has found the same response 
to starvation: in P. falciparum, hibernation without a detectable 
upregulation of Atg8 production was also observed [46,76]. Furthermore, 
the identities of the various punctate structures have not been 
unequivocally determined, so it remains to be determined whether or not 
these structures correspond to classical autophagosomes. 
On the other side of the life/death balance, there is evidence for 
autophagic programmed cell death in response to various signals, 
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including nutrient deprivation, drug treatment, heat stress, and even 
normal cellular events. For example, extensive vacuolization has been 
observed in dying liver stage parasites in mice, though PbAtg8 was not 
found to co-localize with these vacuoles [56]. In late erythrocytic stage 
parasites, heat stress led to cell death without typical signs of apopototic 
cell death, but with the appearance of cytoplasmic vacuoles suggestive of 
an autophagic type of cell death [77]. Prolonged amino acid starvation (4 
h) in growing intracellular T. gondii led to mitochondrial fragmentation 
and loss of invasion competence; these two effects were blocked by the 
autophagy inhibitor, 3-MA [74]. Furthermore, both TgAtg8 and PfAtg8 
exhibited a wider punctate distribution under these conditions [71,74]. 
Additionally, treatment with chloroquine in P. falciparum [78] or 
monensin in T. gondii [79] have both been proposed to lead to autophagy-
related cell death. In particular, treatment with the anti-coccidial 
monensin led to TgAtg8 puncta and mitochondrial degradation that was 
similarly blocked by 3-MA [79]. Taken together, all of these details are 
highly indicative of an autophagic cell death mechanism in response to 
certain cellular environments. 
Much debate still exists over the role of the Atg proteins in 
Apicomplexa, particularly in P. falciparum. Surprisingly, one of the most 
contested roles for autophagy proteins is in canonical macroautophagy, 
as numerous studies have reported both the presence and absence of 
typical markers of autophagy [55]. Nevertheless, it has become 
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increasingly clear that autophagy, even with a more limited repertoire of 
autophagy related proteins, has been adapted and repurposed to serve 
novel roles within the unique life cycles of Apicomplexa, as is the case 
with many fundamental processes in these parasites. 
Finally, it is worth commenting on the interplay between parasite 
and host cell autophagy. From a variety of reports, it appears that host 
cell autophagy may serve both pro-life and pro-death functions for 
apicomplexan parasites. For example, recent results from the Pierce lab 
have shown that inhibiting mammalian target of rapamycin (mTOR) 
blocks the development of experimental cerebral malaria [80]. While 
mTOR is involved in several different conserved pathways regulating 
immune responses, which could be primarily responsible for this 
observation, it would nonetheless be interesting to determine the extent 
to which upregulation of host cell autophagy is involved in this effect. 
 
Targeting the Plasmodial (and apicomplexan) Atg8-conjugation 
pathway 
While much remains to be determined about the function of the 
Atg proteins within Plasmodium and the other Apicomplexa, one fact has 
become clear: whatever their functions, many of the Atg proteins are 
essential in the organisms that have been examined. As mentioned 
earlier, efforts to inhibit or knockdown Atg8 in particular apparently 
result in non-viable parasites [42,43,50]. Inhibiting the association of 
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Atg8 with parasite membranes, such as the apicoplast outer membrane, 
is predicted to be lethal to the cell, as Atg8 is required for proper cell 
function and Atg8’s functional form within the parasite is its lipid-
conjugated form. Therefore interfering with the conjugation pathway that 
leads to Atg8 lipidation, e.g. the Atg3-Atg8 interaction, is an attractive 
target for drug discovery. To obtain insights into the particular protein-
protein interaction between PfAtg3 and PfAtg8, we co-crystallized PfAtg8 
with a peptide of PfAtg3 [81]. The peptide (NDWLLPSY) was identified by 
sequence similarity to be the Atg8 family interacting motif of PfAtg3, and 
it bound, as predicted, to the conserved W/L-site on PfAtg8 [81]. This 
crystal structure (PDB ID: 4EOY), solved to 2.2 Å resolution, revealed the 
presence of a loop region in PfAtg8 that does not exist in the homologous 
human or yeast Atg8 protein structures (Figure 1.2A) [81]. We termed 
this loop the apicomplexan loop, or A-loop, as it is conserved in 
apicomplexan Atg8s but not in human Atg8. It was further determined, 
through mutagenesis and deletion studies, that the A-loop is necessary 
for the interaction between PfAtg3 and PfAtg8. The existence and 
necessity of this loop makes PfAtg8 a feasible target for drug discovery, 
as it provides the required divergence from homologous human 
structures to help prevent off-target effects. This point of divergence is 
important, since the main binding pocket on Atg8 (the W/L-site) is well 
conserved between Plasmodium and human Atg8 protein structures 
(Figure 1.2B). This structural knowledge allowed us to take two 
 20 
approaches towards novel lead discovery against the PfAtg3-PfAtg8 
interaction.  
First, the open access Medicines for Malaria Venture (MMV) 
Malaria box of 200 drug-like and 200 probe-like compounds was 
screened [82]. Using a Surface Plasmon Resonance (SPR) setup, we 
screened all 400 compounds against the PfAtg3-PfAtg8 interaction, 
identifying several compounds that met our criteria for sufficient 
inhibition of this protein-protein interaction [83]. Of these compounds, 
three shared a 4-pyridin-2-yl-1,3-thiazol-2-amine (PTA) scaffold and were 
found to inhibit the PfAtg3-PfAtg8 protein-protein interaction in a dose-
dependent manner [83]. The most soluble of these hits was compound 1, 
2-methylsulfanyl-N-(4-pyridin-2-yl-1,3-thiazol-2-yl)benzamide, with an in 
vitro IC50 of 18.2 µM. Compound 1 bound directly to PfAtg8 and, via 
virtual docking, was predicted to bind to the main binding pocket, the 
W/L-site (Figure 1.2C, D). The plasmodicidal activity of this compound 
was also tested against liver and blood stage parasites and showed an 
IC50 of 1.6 µM against blood stage Plasmodium. Treatment of infected 
liver cells for 96 h with 30 µM compound 1 led to a 50% decrease in the 
proportion of infected hepatocytes, while no effect was detected on liver 
cell viability. Of significant interest is the fact that treatment with 
compound 1 led to a dose-dependent upregulation of PfAtg8 protein level 
along with a shift in lipidation state to primarily unlipidated PfAtg8 as 
assayed via western blot. These data support the suggestion that 
 21 
compound 1 is acting against the predicted target and inhibits the PfAtg8 
and PfAtg3 protein-protein interaction. Based on these promising results, 
we synthesized a 240-compound derivative library, using the PTA 
scaffold with a functional handle, in order to improve binding and 
specificity and to extend the molecule towards regions of the protein that 
are less conserved with the human homologues. In terms of the 
implications for drug development against other Apicomplexa, compound 
1 showed growth inhibitory effects on Cryptosporidium in vitro  [84], 
which suggests that it is also effective against the CpAtg8-CpAtg3 
interaction. This result is not unexpected given the degree of 
conservation in the main binding pocket, which implies that the PTA 
compounds are also predicted to be active against other Atg3-Atg8 
interactions in Apicomplexa. 
In our second approach, we made direct use of the solved crystal 
structure to target the A-loop pocket of apicomplexan Atg8 using a 
virtual ligand screening approach [85]. Using the OpenEye suite of 
software (www.eyesopen.com), we virtually docked the ChemBridge 
Express library (www.chembridge.com) into the volume defined for the A-
loop pocket (Figure 1.2C), specifying two protein contacts and two 
hydrogen bonds to anchor the hits within the pocket. From this initial 
screen, we cherry-picked 14 of the top hits based on visual inspection 
and cost. All of the hits produced some inhibition of the plasmodial 
protein-protein interaction and no inhibition of the homologous human 
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Atg8-Atg3 interaction when tested by SPR binding assays. apicomplexan 
Loop Compound 25 (ALC25) had the most potent effect and was used in 
follow-up assays to determine the in vitro IC50 against the PfAtg3-PfAtg8 
interaction and to test against P. falciparum 3D7 blood and liver stage 
malaria. Its in vitro IC50 was 18.5 µM, and its effect on blood stage 
malaria was similar, with an IC50 of 19 µM. As was the case with PTA 
compound 1, treatment of blood stage parasites with ALC25 led to an 
increase and shift in the lipidation state of PfAtg8 as determined by 
western blot. ALC25 also showed activity against liver stage parasites, 
leading to a 30% decrease in the number of infected liver cells at 96 h 
post-treatment with 30 µM ALC25, while being well tolerated by human 
hepatocyte cell line. We also performed a secondary SPR assay to provide 
evidence for the predicted binding site of ALC25 within the A-loop pocket. 
With the established SPR assay [86], we immobilized a biotinylated 
version of the PfAtg3 peptide to an SPR chip via NeutrAvidin capture – we 
used the same peptide that was co-crystallized with PfAtg8 (PDB ID: 
4EOY). The  expected KD between the peptide and PfAtg8 was re-
established and then it was demonstrated that ALC25 at inhibitory 
concentrations did not disrupt the peptide-PfAtg8 interaction. As the 
peptide was shown to bind to the W/L-site in the crystal structure, this 
provides strong evidence that ALC25 binds to an alternative site. As 
suggested above, these A-loop compounds may have cross-reactivity 
against other Atg8 homologues in the same phylum since they target the 
 23 
conserved loop pocket. Either way, a similar approach would be likely to 
prove fruitful in generating novel leads against other apicomplexan Atg8 
targets. 
Both of our approaches resulted in the identification of novel 
compounds with activity in vitro and in parasite cultures against the 
PfAtg3-PfAtg8 interaction. Our next step is to optimize these leads to 
provide increased binding affinity and specificity. Interestingly, there is 
the possibility of linking these two molecules, or these two sites, as the 
functional handle of the PTA compound derivatives is predicted to point 
toward the A-loop pocket (Figure 1.2D). A drug that would bind to both of 
these sites could have the exact desired qualities of increased specificity 
and affinity. As mentioned above, the greater degree of conservation 
within apicomplexan Atg8 homologues supports our hypothesis that the 
methods suggested here may have broader implications for the discovery 
of new intervention strategies against Apicomplexa in general. 
 
Concluding Remarks 
The last few years have seen a substantial increase in what is 
known about apicomplexan autophagy and the parasites’ interactions 
with their host cells. As apicomplexan autophagy represents a conserved 
and essential pathway in these parasites, it is of significant importance 
on two fronts. First, the sheer fact of its necessity to parasite function 
indicates that autophagy proteins within these organisms have been 
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repurposed to serve novel functions, as many autophagy proteins are not 
essential within other higher-level eukaryotes [13,26]. This hypothesis is 
well supported by the highly documented association of Atg8 with the 
apicoplast, as an association with non-transient organelles is well 
outside of the extent of classical macroautophagy. Second, as was made 
clear in the third section of this review, this conserved pathway, and the 
Atg3-Atg8 interaction in particular, represent fertile ground for the 
discovery of novel anti-apicomplexan small molecule interventions. Two 
such small molecules inhibiting the PfAtg3-PfAtg8 interaction were 
described above with evidence to support the theory that these 
molecules, and the methods by which they were discovered, could have 
broader applications within the Apicomplexa phylum as a whole [81,83] 
(Hain 2016). 
As more is learned about this fundamental pathway, it is likely 
that new targets and intervention strategies will arise, with an emphasis 
on seeking low-cost solutions to the global health issues presented by 
Apicomplexa. Such low-cost interventions are of critical importance on 
the global scale, as many of the countries continually plagued by malaria 
and other apicomplexan diseases do not have the financial means to 
afford the high cost therapies that arise from pharmaceutical brute force 
drug discovery. For this reason, virtual docking will continue to be a 
useful tool within this field, as making use of computational tools could 
be expected to reduce drug development costs by up to 50 percent [87]. 
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On a final note, it is also worthwhile to comment on the connection 
between this research and potential applications to human autophagy 
interventions. Defects in autophagy have been linked to a number of 
important human diseases, including immune disorders [88], heart 
disease [89], neurodegenerative diseases [90], and most notably, cancer 
[91,92]. As appears to be a repeating trend, autophagy has been found to 
serve both pro-survival and pro-death functions within various cancer 
types [91,92]. Due to its pro-survival role, autophagy has recently 
become an important target for new cancer therapies. Because of this, 
our research has had potential applications to human cancer, a 
connection also made for other antimalarials [93,94]. For example, in the 
process of screening the VLS compounds against the human LC3-Atg3 
interaction, we discovered a compound that would not be appropriate as 
an antimalarial due to its activity against the human interaction [85]. As 
regions of Atg8 are well conserved between Plasmodium and human 
homologues, it is only natural that small molecule screening against one 
target will have the added benefit of potentially uncovering inhibitors 
against the other target.  
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Figures 
Figure 1.1. An overview of canonical macroautophagy in yeast and 
Plasmodium. (A) Step 1: induction and phagophore assembly. The Atg1 
complex forms at the PAS, leading to recruitment and activation of the 
PI3K class III complex. The PI3K complex converts PI to PI3P in the 
phagophore membrane resulting in Atg2, Atg18, and Atg9 binding. Step 
2: phagophore elongation and closure to form the autophagosome. This 
step relies on Atg8 being conjugated to PE. Atg8–PE is the product of the 
Atg8 conjugation pathway, the last step of which is facilitated by Atg12–
Atg5-Atg16. Atg12–Atg5 is the product of the Atg12 conjugation pathway. 
Step 3: autophagosome fuses with the lysosome to form an 
autolysosome. Step 4: digestion of autolysosomal contents and release of 
recycled amino acids. Atg15 and Atg22 facilitate breakdown of the 
membrane-bound vesicle within the autolysosome to expose the contents 
for digestion. The products of digestion, amino acids, are then released 
into the cell. (B) Conservation of canonical macroautophagy proteins 
within Plasmodium [17,55]. Bold text on a green background indicates a 
conserved homologue exists; regular text on a yellow background, 
potential homologues identified; italics on a red background, no 









Figure 1.2. Plasmodium and apicomplexan Atg8 proteins. (A) Multiple 
sequence alignment of various apicomplexan, human, and yeast Atg8 
homologues generated by ClustalW2 
(http://www.ebi.ac.uk/Tools/msa/clustalw2/). Visualized with ESPript 
3.0, with global score set to 0.4 (espript.ibcp.fr). Ovals indicate side chain 
contacts in the three pockets on PfAtg8; triangles indicated backbone 
contacts in these pockets. Magenta corresponds to the W-site pocket; 
cyan, the L-site pocket; and yellow, the A-loop pocket.  The A-loop itself 
is outlined in yellow, revealing conservation of the A-loop within 
apicomplexan, but not in human or yeast homologues. The C-terminal 
glycine is indicated by a black asterisk, illustrating that this glycine is 
exposed in most apicomplexan Atg8 homologues, but not in C. parvum, 
human or yeast Atg8. (B) Conservation of pockets on PfAtg8 (PDB ID 
4EOY) generated using Consurf with the default values 
(consurf.tau.ac.il). The W- and L-sites are highly conserved, while the A-
loop pocket is not. (C) Structure of PfAtg8 color-coded as in (A): magenta, 
W-site; cyan, L-site; yellow, A-loop pocket. The pink region between the 
W- and L-sites indicates residues involved in both sites. (D) Electrostatic 
surface representation of PfAtg8 rendered using OpenEye Vida and POV-
Ray (povray.org). Predicted binding modes of one of the PTA ligands, 
bound in the W- and L-sites, and ALC25, bound in the A-loop pocket. 
From these poses, it appears there is the potential to link the two sites. 
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New therapies are needed against malaria, a parasitic infection 
caused by Plasmodium falciparum, as drug resistance emerges against 
the current treatment, artemisinin. We previously characterized the 
Atg8–Atg3 protein-protein interaction (PPI), which is essential for 
autophagy and parasite survival. Herein we illustrate the use of virtual 
library screening to selectively block the PPI in the parasite without 
inhibiting the homologous interaction in humans by targeting the A-loop 
of PfAtg8. This A-loop is important for Atg3 binding in Plasmodium, but is 
absent from the human Atg8 homologues. In this proof-of-concept study, 
we demonstrate a shift in lipidation state of PfAtg8 and inhibition of P. 
falciparum growth in both blood- and liver-stage cultures upon drug 
treatment. Our results illustrate how in silico screening and structure-
aided drug design against a PPI can be used to identify new hits for drug 
development. Additionally, as we targeted a region of Atg8 that is 
conserved within apicomplexans, we predict that our small molecule will 
have cross-reactivity against other disease-causing apicomplexans, such 





Malaria continues to be a major public health and economic 
burden in the developing world, resulting in over half a million deaths 
each year, most of which are caused by the Plasmodium falciparum 
species of the malaria parasite [95]. Currently, artemisinin combination 
therapy is the first-line defense for P. falciparum malaria in most 
countries. As was the case for previous antimalarials such as 
chloroquine (CQ), resistance is emerging against artemisinin and has 
been detected in five countries in Southeast Asia [36,95]. It is critical to 
have new and effective therapies ready as resistance inevitably spreads to 
other parts of the world. 
Plasmodium is a member of the phylum Apicomplexa, a group of 
parasitic protists characterized by their possession of an apical complex 
involved in host cell invasion. These organisms also frequently contain a 
unique plastid organelle called the apicoplast. A number of apicomplexan 
organisms cause parasitic infections that pose a threat to young children 
and immune-suppressed individuals. For example, Toxoplasma gondii, 
the causative agent of toxoplasmosis, asymptomatically infects up to a 
third of the world's population and, though harmless in healthy 
individuals, can be fatal when the immune system becomes 
compromised [96]. Additionally, species of Cryptosporidium are 
responsible for the majority of parasitic protozoan water-borne outbreaks 
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globally [32], with limited treatments for young, malnourished, or HIV-
infected patients [97]. 
Apicomplexans pose a threat not only to human health. Babesia, 
Eimeria, Neospora, and Theileria species are important veterinary 
pathogens in countries across the globe, resulting in significant economic 
burdens to the livestock and poultry industries. Neospora caninum, for 
example, is a significant contributor to cattle abortion, resulting in losses 
of over $500 million annually in the United States dairy industry [35]. 
Recent work has shown the autophagy pathway is conserved and 
essential in both P. falciparum and T. gondii [47,48,50,98]. While in 
higher-level eukaryotes, autophagy is primarily a degradation pathway 
for bulk cytoplasm, protein aggregates, and damaged organelles, 
apicomplexans have adapted this pathway to serve diverse purposes 
specific to the parasite lifecycle [43,45,47,48,50,54,98]. Because the 
autophagy machinery in these organisms is more conserved across 
apicomplexan organisms than between apicomplexans and humans, we 
identified a target that would allow for the inhibition of autophagy across 
parasite species. Our first proof-of-concept study was recently published 
with data on P. falciparum [81,83]. Our previous hit, N-(4-methylphenyl)-
4-pyridin-2-yl-1,3-thiazol-2-amine, identified from the Medicines for 
Malaria Venture Malaria Box [82], was also shown to have growth 
inhibitory effects on Cryptosporidium cultures [84], suggesting that the 
CpAtg8–CpAtg3 interaction might be required in this organism, as well. 
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Atg8 is an essential component of the core autophagy machinery. 
In yeast and other eukaryotic organisms, its main role is in the 
expansion and closure of the autophagic vesicle, or autophagosome, 
which sequesters material to be degraded in the vacuole [17,46]. Atg8 is 
covalently attached to the autophagosome membrane through a series of 
intermediate thioester formations with its E1-activating enzyme, Atg7, 
and E2-conjugating enzyme, Atg3. The biologically relevant form of Atg8 
is thus its lipidated form, which has been shown to be the predominant 
species within P. falciparum parasites; however, evidence suggests that 
PfAtg8 does not play the same role within autophagy, despite its 
essentiality [44,45,53,54]. 
In order to lipidate Atg8, Atg3 interacts with two conserved 
hydrophobic pockets on Atg8, termed the W- and L-sites. We previously 
identified an additional region in Plasmodium Atg8 that is important for 
the interaction with plasmodial Atg3. This region was termed the A-loop, 
as it is conserved in apicomplexans and absent in human homologues 
(Figures 2.1 and 2.2) [81]. This divergence provides the opportunity for 
specificity and selectivity in developing anti-apicomplexan inhibitors. 
Virtual ligand screening (VLS), an in silico method in which 
compounds are computationally docked to a known protein structure, is 
increasingly used in the drug development field [99]. We used the X-ray 
structure of P. falciparum Atg8, PDB ID: 4EOY [81], as a template for the 
VLS. Using this method, we identified compounds that inhibit the Atg8–
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Atg3 interaction in P. falciparum without inhibiting the homologous 
interaction in humans. Because of the sequence conservation to other 
disease-causing parasites, such as Toxoplasma and Cryptosporidium, we 
predict that inhibitors developed against this target could be cross-
reactive with other parasites. Targeting protein regions conserved across 
disease-causing organisms using structure-aided drug design has the 
potential to identify compounds with cross-species reactivity. 
 
Results and Discussion 
Virtual docking used to select 14 compounds for testing 
To identify potential PfAtg8–PfAtg3 inhibitors, we undertook VLS 
against the co-crystal structure of PfAtg8 with a peptide of PfAtg3 (PDB 
ID: 4EOY). We removed the peptide and used the structure of PfAtg8 as 
the receptor in docking. Multiple sequence alignment and structural 
analysis revealed a region of Atg8, termed the A-loop, which is conserved 
within Apicomplexa, but absent from human homologues (Figures 2.1 
and 2.2). Therefore, docking was constrained to the A-loop pocket 
(Figure 2.3A,B). To constrain it to the A-loop, we specified that the small 
molecules have two backbone hydrogen bond interactions within the A-
loop (His67, Ile68), and two side chain residues (Lys46 and Glu45) were 
selected as contacting residues for the docking algorithm to ensure that 
the search was targeted to the specific pocket of interest. The His67 and 
Ile68 backbone interactions are sequence independent; their selection 
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was intended to bias the search toward hits that could have an effect on 
multiple apicomplexan Atg8 homologues. These residues have the added 
benefit of being absent from the human homologues, which increases the 
chances for limited off-target effects. 
The ChemBridge library (July 2012) contained 369,632 descriptors 
for small molecules, from which 10,848 were considered toxic or reactive 
using the default filter algorithm of the program FILTER from the 
OpenEye suite [100]. A property characterization of the filtered VLS 
library is represented in Supporting Information Figure 2.S1A-C. The 
final conformer library used for docking studies contained on average 
816 conformers per small molecule, resulting in a total of 546,161,945 
docking trials tested by FRED (Supporting Information Figure S2.1D) 
[101]. The default Chemgauss 4 scoring algorithm was used to rank the 
hits from VLS. The hits were further ranked according to known toxicity 
data, predicted solubility, balance between polar/apolar interactions, 
and to achieve maximal diversification. Of 29 molecules selected based 
on this ranking, we were able to obtain 14 from commercial sources for 
further in vitro and in vivo parasite testing (Table 2.1). Figure 2.3C 
summarizes the workflow for this selection process. 
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Surface Plasmon Resonance (SPR) interaction assay confirms in 
vitro inhibition by apicomplexan loop compound 25 (ALC25) 
We tested the 14 VLS hits for in vitro inhibition of the plasmodial 
Atg8–Atg3 interaction using our established SPR competition assay 
(Figure 2.4A) [81]. Binding is measured by SPR response of an injection 
of purified PfAtg8 alone or in the presence of small molecules over 
immobilized PfAtg3; 13 of the 14 compounds inhibited the PfAtg3-PfAtg8 
interaction (Figure 2.4B). 
The molecules were further tested for inhibition of the homologous 
human interaction between hLC3 and hAtg3. None of the compounds 
inhibited hAtg3-hLC3 binding (Figure 2.4C). We observed that some of 
the compounds (ALC11, ALC13, ALC19, ALC20, and ALC30) either 
precipitated or caused protein precipitation at the concentration tested in 
the assay. These compounds are indicated in blue in Figure 2.4B,C and 
were not further pursued. The effect of the molecules on the plasmodial 
and human interactions was plotted in a two-species inhibitor/stabilizer 
(TSIS) plot for ease of comparison (Figure 2.4D). 
 
Dose dependency, direct binding, and interaction site of ALC25 
confirmed in vitro by SPR, thermal stability assay, and ITC 
ALC25 and ALC24, the best hits, were chosen for verification of 
dose-dependent inhibition of the interaction. ALC24 led to a notable 
increase in binding for the human interaction, suggesting that it would 
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not be viable as an antimalarial. However, because ALC24 interferes with 
the human interaction by significantly stabilizing the binding of hLC3 to 
hAtg3, it may have applications in certain cancer therapies, as 
autophagy has been linked to cancer survival, proliferation, and growth 
[91,92]. In terms of the plasmodial Atg8–Atg3 interaction, of the two 
compounds, only ALC25 led to dose-dependent inhibition of plasmodial 
Atg8–Atg3, with an SPR IC50 value of 18.5±2.1 µM (Figure 2.5A). 
Direct binding of ALC25 was tested using thermal shift assays on 
the protein PfAtg8CM, a construct with three cysteine residues mutated to 
isoleucine or serine for stability (the construct for the crystal structure 
[81]). ALC25 led to a dose-dependent decrease in the Tm, which suggests 
direct binding to PfAtg8, but also indicates that the compound may not 
be well-suited for co-crystal matrix screening (Figure 2.5B). This decrease 
in Tm could be the result of engaging Lys46 (one of the docking 
constraints) away from the W-site, leading to a slight destabilization of 
the protein core. 
To confirm that ALC25 does not bind to the W/L site of PfAtg8, we 
used an established SPR assay [86] to determine whether ALC25 
interferes with the binding of the PfAtg3 peptide to PfAtg8. The PfAtg3 
Atg8-interacting-motif peptide (NDWLLPSY) was previously co-
crystallized with PfAtg8 and shown to bind in the W/L site of PfAtg8 
(PDB ID: 4EOY) [81]. Avitag-PfAtg3 peptide was biotinylated and 
immobilized on an SPR chip coated with NeutrAvidin. To validate that 
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our Avitag-PfAtg3 chip was functional, we passed recombinant PfAtg8 
over the chip and observed binding and dissociation from the chip, which 
were in agreement with our previously reported results [81]. To assess 
whether or not ALC25 binds to the W/L site, we passed PfAtg8 over the 
PfAtg3 peptide in the presence of 1 mM ALC25 and observed no 
inhibition of the interaction (Figure 2.5C). This, along with our docking 
results, suggests that ALC25 binds predominantly to the apicomplexan 
loop region on PfAtg8. Of note, ALC25 had the second-highest ranking 
overall in the original docking screen. The docking pose of ALC25 and its 
interactions with the pocket are shown in Figure 2.6. 
While this SPR assay confirmed that ALC25 does not bind to the 
W/L site, we used ITC to show that the loop itself is involved in binding. 
We titrated 50 µM ALC25 into a solution of 5 µM PfAtg8CM and 
PfAtg8CM/LD, which is identical to the CM construct except for a deletion 
of nine amino acids involved in the A-loop: residues 69-77 (NQSAYGSNM) 
[81]. Although PfAtg8 is not well-suited to ITC due to its low solubility, 
we nevertheless observed heat due to binding that could be fit to a one-
site binding model for the wild-type protein, whereas we observed no 
appreciable binding for the loop deletion mutant, thus confirming the 
role of the A-loop in ALC25 binding (Supporting Information Figure S2.2). 
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ALC25 exhibits modest inhibition in P. falciparum cultures 
We measured growth inhibition of P. falciparum 3D7 blood-stage 
cultures by ALC25 using the SYBR green I assay, which measures 
binding of a fluorescent dye to parasite DNA [102]. In our assay, the well-
established antimalarial CQ had an IC50 value of 3±2 nm. ALC25 was 
less potent, with an IC50 value of 19±6 µM (Figure 2.7A). 
In other species, drug inhibition of autophagy leads to an increase 
in Atg8 protein levels, as Atg8 cannot be degraded and the cell up-
regulates Atg8 expression [103]. To confirm that ALC25 was affecting 
PfAtg8 in the parasite, we probed the lipidation status and protein level 
of PfAtg8 with a 4-20^% acrylamide gel and immunoblot analysis. After a 
five-hour treatment with 100 µM ALC25, PfAtg8 protein levels increased 
over 10-fold relative to the DMSO-treated control. Additionally, the 
mobility of Atg8 was retarded, indicative of the unlipidated Atg8 species 
(Figure 2.7B,C) [104,105]. 
It has previously been reported that PfAtg8 partially localizes to the 
apicoplast during exoerythrocytic development of Plasmodium in 
hepatocytes [56]. As the apicoplast is an essential organelle for 
Plasmodium survival, we hypothesized that Atg8 could serve an 
important role in growth during the liver stage. We next assessed the 
effect of ALC25 on the in vitro development of P. falciparum 
exoerythrocytic forms (EEFs) using a transgenic parasite strain 
expressing GFP throughout its life cycle [106]. While ALC25 had little 
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effect on GFP fluorescence intensity, the number of infected HC-04 cells 
detected by flow cytometry 96 hours post-infection was decreased by 
30^% in hepatocyte cultures treated with 30 µM ALC25 (Figure 2.8A). In 
contrast, ALC25 did not affect cell viability of HC-04 cells after a 96-hour 
treatment (Figure 2.8B). 
 
Conclusions 
Autophagy is a catabolic process performed by eukaryotic cells in 
order to maintain homeostasis and to degrade unwanted or toxic cellular 
content, such as misfolded proteins [107]. The autophagy pathway has 
been demonstrated to be important for various functions in yeast and 
humans [107,108], but studies in the past five years have also shown 
that autophagy is necessary in human pathogens, such as Plasmodium 
[17,44,53]. 
In the process of drug discovery, promiscuity, pleiotropy, and 
polypharmacology continue to be a problem. Many of the drugs currently 
used as autophagy inhibitors, such as 3-methyladenine or CQ, are 
promiscuous compounds. Other autophagy modulators, such as 
rapamycin and wortmannin, are inherently pleiotropic as their protein 
targets (mTor and VPS34/Beclin1, respectively) are effectors of multiple 
pathways [109–111]. Beclin1, in particular, may have an autophagy-
independent function [112,113]. Furthermore, polypharmacology, the 
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interaction of drugs with multiple protein targets, is a concern for many 
FDA-approved drugs [114]. 
Related to these concerns, current intervention methods targeting 
the autophagy pathway are somewhat indirect and intervene very early in 
the process of inducing autophagy, which may allow the cell to regulate 
the autophagy pathway through later checkpoint events. Targeting 
downstream events is attractive in circumventing this potential pitfall. 
Autophagy inhibitors that specifically prevent autophagosome expansion 
have been reported in humans and are being considered for anticancer 
drug therapy [115]. 
Our recently identified antimalarial compounds with a 
pyridinylthiazolamine (PTA) scaffold inhibit the critical 
phosphatidylethanolamine (PE)-conjugation step of LC3/Atg8 by its E2-
conjugating enzyme, Atg3.[83] Our PTA compounds were designed to 
interfere with the Atg8–Atg3 protein-protein interaction (PPI) and thereby 
prevent the lipidation of Atg8. Only this lipidated form of Atg8 is active: it 
participates in elongation of the autophagosomal membrane in higher 
eukaryotes, and is the predominant species in Plasmodium [44,45,53,54]. 
Our bioinformatics analysis suggests that the autophagy pathway 
is conserved in multiple human and livestock pathogens and likely 
fulfills important functions in these organisms. 
We used an in silico approach to target the A-loop pocket of PfAtg8. 
This approach led to the discovery of a compound that inhibits the in 
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vitro Atg8–Atg3 interaction in Plasmodium and shows activity in blood 
and liver stages. Although the potency is in the micromolar range, ALC25 
was well tolerated by a human hepatocyte cell line at these 
concentrations. The IC50 values of ALC25 against the in vitro PPI and 
against blood-stage parasite growth in vitro are in good agreement, 
suggesting that ALC25 may target the Atg8–Atg3 interaction in vivo. In 
support of this, ALC25 led to accumulation of the unlipidated Atg8 
species as quantified by western blot with specific antibodies, a 
phenomenon previously observed for another inhibitor of this PPI [83]. 
We now have the opportunity to proceed with lead optimization of a small 
molecule derived from VLS based on in vitro validation and apparent on-
target effect in parasite cultures. In addition, we show that two 
independent drug discovery pathways result in different small-molecule 
entities capable of interfering with the process of Atg8 lipidation. 
It remains to be tested whether ALC25 has cross-reactivity against 
other apicomplexan species. However, our bioinformatics analysis 
suggests ALC25 may have activity against Eimeria, 
Toxoplasma/Neospora, Cryptosporidum, Theileria, and Babesia 
(Figure 2.2C). 
The importance and feasibility of targeting PPI interfaces has 
become increasingly clear over time [116,117]. In this case, we 
demonstrate that the development of PPI inhibitors is a promising and 
viable strategy for future lead identification using orthogonal screening 
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and validation methods. Our structural models support the hypothesis 
that it may be possible to bridge the W/L site, occupied by the PTA 
molecule, with the A-site, occupied by ALC25. A molecule that interacts 
with both sites would be predicted to have increased potency and provide 
selectivity toward the parasitic Atg8 proteins, as the A-loop is absent in 
human homologues. 
 
Materials and Methods 
Bacterial strains and culture conditions. Escherichia coli strains 
were cultured in Terrific Broth (TB) medium supplemented with 
50 µg/mL ampicillin or kanamycin as appropriate. All proteins were 
expressed using the E. coli Rosetta 2 strain, which has an additional 
plasmid for expressing rare codons with a chloramphenicol-resistance 
cassette; cultures were thus additionally supplemented with 34 µg/mL 
chloramphenicol. 
Plasmid and strain construction. The plasmids and strains used 
to express hLC3, PfAtg8, and PfAtg3 have been described previously [81]. 
hAtg3 was received from the Johns Hopkins Genetic Resources Core 
Facility on a pENTR221 vector. The gene was PCR amplified using 
custom primers 5'-CATG CCAT GGGC CAGA ATGT GATT AATA CTGT 
GAAG GGAA (sense) and 5'-cgcg gatc cgtt acat tgtg aagt gtct tgtgt agtc 
(antisense). The PCR fragment was digested with New England BioLabs® 
(NEB) NcoI and BamHI restriction enzymes, and then ligated with NEB 
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T4 DNA ligase into a modified pRSF vector containing an N-terminal 
maltose binding protein (MBP) tag followed by a tobacco etch virus (TEV) 
protease cleavage site [86]. The plasmid was then transformed into 
chemically competent E. coli Rosetta 2 cells. 
Protein expression and purification. For hLC3, PfAtg8, and 
PfAtg3, expression and purification were performed as previously 
described [81]. After transformation of hAtg3, a single colony was 
selected and sequence verified. Cells from this stock were grown in TB 
media with 50 µg/mL kanamycin and 34 µg/mL chloramphenicol. Cells 
were grown in the presence of 1% glucose at 37°C, shaking at 250 rpm 
until an OD600 of 3.0 was reached. At this point, the cells were induced 
with 0.5 mM IPTG and then continued growing overnight at 20°C with 
shaking. All steps after overnight incubation were conducted at 4°C. The 
cells were harvested by centrifugation at 1300 g for 45 min and 
resuspended in lysis buffer: 10 mM HEPES (pH 7.5), 150 mM NaCl, 
1 mM DTT with one tablet of Roche® Complete EDTA-free protease 
inhibitor per 100 mL and 10 U benzonase (Sigma-Aldrich®). Using an 
Avestin® EmulsiFlex-C5 cell disruptor, the cells were lysed at 15 kpsi 
(100 MPa). This lysed solution was cleared at 18,000 g for 45 min, after 
which the supernatant was decanted to incubate with amylose resin 
(NEB) for 30 min. The resin was washed with lysis buffer before the 
protein was incubated for 30 min with elution buffer (lysis buffer with 
10 mM maltose). Eluted hAtg3 was cleaved with homemade TEV protease 
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at a mass ratio of 1:100, while simultaneously dialyzed into 10 mM 
HEPES (pH 7.5), 100 mM NaCl, 1 mM DTT. After cleaving, hAtg3 was 
separated from MBP and TEV protease by anion exchange using a 
RESOURCETM Q column (GE® Healthcare) on an ÄKTATM purifier system. 
Purified proteins were analyzed by SDS-PAGE and quantified using a 
Nanodrop (ThermoFisher®) spectrophotometer at λ=280 nM using the 
molar extinction coefficient for each of the proteins as calculated from 
the primary sequence by ProtParam [118]. For SPR, proteins were 
concentrated to 1-3 mg/mL and buffer exchanged into the indicated 
running buffer. 
VLS with FRED. The OpenEye suite of programs [100] was used to 
prepare an in silico library of the ChemBridge commercial small-molecule 
database. Structure description files (.sdf) were obtained from 
ChemBridge and first subjected to the OpenEye FILTER program for 
removal of small molecules with known toxic and reactive groups. Next, a 
conformer library was generated using OMEGA2 [119] with a maximum 
of 2000 conformers per small molecule and otherwise using default 
parameters. This conformer library was then docked against the co-
crystal structure of PfAtg8–PfAtg3, PDB ID: 4EOY [81], after removing the 
PfAtg3 peptide and water molecules. The protein receptor was generated 
with OpenEye's make_receptor program using default values and adding 
restraints in the form of two backbone interactions and two side chain 
contacts within the apicomplexan loop pocket to serve as anchoring 
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points for the docking (Figure 2.3A,B). Docking was carried out on a 24 
core MacPro using FRED [101] with default settings using a fine grid of 
0.5 Å. Visualization and inspection of the top-500 docking results was 
carried out with OpenEye's visualization software, VIDA. A selection of 29 
molecules were cherry picked, from which 14 were readily available from 
commercial sources for testing in biochemical and biophysical assays 
(Table 2.1). 
SPR PPI assay. All measurements were carried out on a BiaCore 
3000 instrument at 25°C. We used the previously described SPR 
competition assay [81] to test inhibition of the PfAtg8–PfAtg3 and hLC3-
hAtg3 interactions. The standard running buffer was 10 mM HEPES, 
150 mM NaCl, 0.01% Tween 20, adjusted to pH 7.5. Prior to performing 
SPR assays, all solutions were sterile filtered and degassed for 1 h at 
room temperature. For small-molecule inhibitor studies, the same 
running buffer was supplemented with 1% DMSO. All dose-dependency 
measurements were carried out in triplicate and corrected for DMSO 
absorption effects using double referencing with interspersed blank 
injections and an untreated flow cell on the SPR chip and the SPR 
analysis software Scrubber 2.0 (BioLogicTM). For each interaction pair, a 
new CM5 SPR chip was used. To exclude surface decay during the 
experiment, positive control injections were interspersed every 12th 
injection. For all interaction studies, the Atg3 homologue was 
immobilized, and the corresponding Atg8 partner was passed as an 
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analyte over the chip in either the presence or absence of small-molecule 
inhibitors, dissolved to 100 mM in 100% DMSO and tested at 500 µM 
final concentration. Prior to the immobilization of Atg3 to an SPR chip, a 
pH scouting from pH 6.0 to pH 4.0 in intervals of 0.5 pH units was 
carried out to determine the best pre-concentration conditions for 
immobilization. Briefly, flow cells of an SPR chip were activated using N-
hydroxysuccinimide (NHS) and 1-ethyl-3-(3-
dimethylaminopropyl)carbodiimide (EDC) for 7 min at a flow rate of 
20 µL/min. For PfAtg3 immobilization, a solution of 50 µg/mL PfAtg3 in 
10 mM sodium acetate (pH 5.0) was passed over one flow cell until >500 
response units (RU) were captured. The same procedure was followed for 
the immobilization of hAtg3. Activated free binding sites on the chip were 
blocked using 1M ethanolamine for an additional 7 min. All experiments 
were carried out at 25°C at a 40 µL/min flow rate and 75 s contact time, 
followed by a 1 min dissociation time and a 25 µL regeneration injection 
of 2M MgCl2. The dose-response curves were used to determine the 
approximate concentration of analyte (PfAtg8 or hLC3) needed to obtain a 
particular RU value, typically in the range of 100-150 RU. A fixed 
amount of analyte was then passed over the chip resulting in at least 
100-150 RU in the absence of small molecules. 
TSIS plot. To determine which inhibitors to pursue after the initial 
screen, it is useful not only to consider the variance of the control 
response (to determine if the inhibited response differs significantly from 
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the control), but also to consider the inherent variability in the non-
control responses, which is a function of many features, including the 
density of active protein on the chip. To do this, we considered the 
standard deviation of the non-control responses as a means by which to 
detect compounds that perform significantly better or worse than the 
majority. In this case, we pursued an inhibitor that performed 
significantly better at inhibiting the Plasmodium interaction while not 
interfering with the human interaction. We compared both responses 
normalized to their respective controls, with human plotted on the x-axis 
and P. falciparum on the y-axis. Each point corresponds to the average 
response in the presence of one compound, with error bars 
corresponding to the standard deviation in the individual measurements. 
The black rectangle in the graph encloses responses that are within one 
standard deviation of the average non-control response. 
Thermal shift assay. Small molecules identified from our VLS 
approach were tested in thermal stability assays in 1×PBS with 1:1800 
final dilution of SYPRO orange dye (Invitrogen), with 65 µM His6-
PfAtg8CM. Triplicate measurements of fluorescence were measured from 
20 to 80°C in a Bio-Rad C1000 thermal cycler for each concentration. 
ALC25 was added at increasing concentrations ranging from 100 µM to 
2 mM, with DMSO concentration kept constant in all samples. 
ALC25 binding site verification by SPR peptide-protein 
interaction assay. The peptide sequence NDWLLPSY of PfAtg3 
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(PlasmoDB gene ID: PF3D7_0905700.1), as co-crystallized in complex 
with PfAtg8 (PlasmoDB gene ID: PF3D7_1019900), PDB ID: 4EOY,[81] 
was synthesized and cloned into a pRSF-1b plasmid yielding Avitag-
PfAtg3 as previously described [86]. Avitag-PfAtg3 was expressed in TB 
media and induced with 1 mM IPTG for 16 h at 20°C. Cells were lysed 
using an Avestin cell disruptor. The cell lysate was passed over TALON 
CellThru resin functionalized with Co2+ to capture the N-terminal His12 
tag of the recombinant Avitag-PfAtg3 construct. The eluted samples were 
validated by SDS-PAGE and directly used for capturing to a NeutrAvidin-
coupled CM5 chip. A single lysine residue on the Avitag is biotinylated 
and forms a tight interaction with the NeutrAvidin on the chip. All 
interaction studies with the Avitag-PfAtg3 CM5 chip were performed in 
10 mM HEPES (pH 7.5), 150 mM NaCl, 3 mM EDTA, 1% DMSO. 
ITC binding assay with ALC25. PfAtg8CM and PfAtg8CM/LD were 
purified as previously described, and then dialyzed into a solution of 1× 
PBS overnight. ALC25 (100 µM) was titrated 10 µL at a time into a 
solution (1.8 mL) of the appropriate protein (10 µM) with a MicroCal VP-
ITC machine (Malvern Instruments Inc., Westborough, MA, USA). The 
injections were 20 s in duration and spaced by 2 min. The jacket 
temperature was maintained at 25°C throughout. Data were analyzed 
and fit using Origin software (version 7.0, OriginLab, Northampton, MA, 
USA). 
 52 
Plasmodium parasite growth inhibition assay. P. falciparum 3D7 
parasites were cultured as previously described [83]. Briefly, the 
parasites were cultured in 10% v/v human serum with 10 µg/mL 
gentamycin and synchronized with 5% w/v sorbitol; 1.5% ring-stage 
parasites were added to 96-well plates (Costar) containing serial 
dilutions, performed in triplicate, of compound in RPMI 1640 media 
(Gibco). Plates were incubated at 37°C in 5% O2, 5% CO2, and 90% N2 for 
72 h. Plates were frozen, thawed, and incubated with 100 µL 2×SYBR 
green in lysis buffer (20 mM Tris pH 7.5, 5 mM EDTA, 0.008% Saponin, 
0.08% Triton X-100) in the dark for 1 h. Fluorescence was measured 
with a plate reader (HTS 7000, PerkinElmer) at excitation/emission 
wavelengths of 485/535 nm. 
Immunoblot analysis of P. falciparum FCR3 blood-stage 
parasites. Immunoblot was performed as per protocol previously 
described [83], with 100 µM ALC25 or equivalent DMSO treatment for 
5 h. In analyzing the quantity of PfAtg8 on the gel, intensity was 
normalized to total protein amount in the protein stain with ImageJ 
[120]. 
Detection of P. falciparum EEFs in vitro. HC-04 human 
hepatocyte cell line (ATCC, Manassas, VA, USA) was maintained in 
complete medium (IMDM containing 2.5% FCS, 100 U/mL penicillin, 
100 µg/mL streptomycin, and 2 mM l-glutamine, all from Gibco Life 
Technologies, Grand Island, NY, USA). P. falciparum 3D7HT-GFP parasite 
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strain [106] was propagated in the Parasitology Core facility of the Johns 
Hopkins Malaria Research Institute. In vitro infection of human 
hepatocytes, as well as detection and quantification of P. falciparum 
3D7HT-GFP EEFs by flow cytometry, were performed as previously 
described [121]. 
Hepatocyte cytotoxicity assay. Hepatocyte cytotoxicity assays 
were carried out in triplicate at two concentrations of inhibitory 
compounds using HC-04 cells as previously described [83]. Flow 
cytometry was used to assess two cytotoxicity markers by staining, 
namely propidium iodine (PI) and Annexin V. 
Web servers and software. Amino acid sequences of apicomplexan 
Atg8 proteins were retrieved from EuPathDB [39] using the NCBI BLAST 
similarity search function [122] to find proteins homologous to PfAtg8. 
Sequences of human Atg8 homologues were retrieved from UniProt [123]. 
Sequence alignments (Figure 2.1A,B) were performed using the ESPript 
multiple sequence alignment web server (http://espript.ibcp.fr) [124]. 
Clustal Omega was also used in sequence comparison (Figure 2.2C) 
[125]. FlowJo software was used in the analysis of flow cytometry data 
(Figure 2.8) [126]. The plot for Figure 2.4D was generated using Matlab 
[127], and all bar graphs and concentration curves were generated using 
GraphPad Prism [128]. Western blot quantification was performed with 
ImageJ (Figure 2.7B) [120]. Figure 2.3B was produced with OpenEye 
VIDA and rendered with POV-Ray [129], Figure 2.6A was produced with 
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OpenEye VIDA, and all other molecular graphics were created with 




Table 2.1: Small Molecule Probes of the Apicomplexan Loop Pocket 
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Figures 
Figure 2.1. Atg8, a pan-apicomplexan drug target. (A) Atg8 sequence 
alignment for ten species of Plasmodium (ESPript, global score set to 0.9). 
P. cynomolgi has a 16-residue non-conserved N-terminal extension not 
shown here. The sequence is color-coded to indicate residues involved in 
ligand interaction sites: magenta, green, and orange correspond to the 
W-, L-, and A-sites, respectively. Ovals indicate side chain interactions, 
and triangles indicate backbone interactions involved in each site. The 
yellow box encloses the A-loop. (B) Sequence alignment of the A-loop in 
several apicomplexan species and human homologues (ESPript, global 
score set to 0.4). Note that the N. caninum and T. gondii Atg8 amino acid 







Figure 2.2 The apicomplexan loop site. (A) Structure of PfAtg8 (PDB 
ID: 4EOY) color coded as in Figure 2.1A, showing the ligand interaction 
sites. B) Comparison of PfAtg8 (PDB ID: 4EOY) and hLC3 (PDB ID: 2ZJD) 
structures, illustrating A-loop divergence. The yellow loop corresponds to 
the yellow box delineated in Figure 2.1. (C) A-loop pocket of PfAtg8 color-
coded based on conservation with five apicomplexan homologues. Green: 
identical or backbone interaction; yellow: conserved mutation; red: 






Figure 2.3 Generation of an in silico PfAtg8 receptor for docking 
studies. (A) PfAtg8 model used in OpenEye docking, with docking 
restraints indicated by green and magenta spheres. Side chain 
interaction: green; backbone interaction: magenta. (B) A-loop pocket size 
characteristics. The left image is oriented as in panel (A). (C) VLS flow 






Figure 2.4 PPI inhibition assayed by SPR. All binding responses are 
normalized to the baseline control at 100%. (A) Schematic of SPR 
interaction study. The two images illustrate SPR interactions in the 
absence (left) and presence (right) of compound. (B) Effect of compounds 
on PfAtg8-PfAtg3 interaction. The green dotted line corresponds to 
control response. Blue indicates some precipitation of protein or 
compound observed at 500 µM concentration. (C) Effect of compounds on 
hAtg3-hLC3 interaction. Green: control; blue: observed precipitation. 
(D) The TSIS plot for human and P. falciparum data. Human (x-axis) 
versus Plasmodium (y-axis) normalized SPR binding. Dotted lines are the 
control response. The gray rectangle encloses compounds within one 
standard deviation of average inhibited response. The green rectangle 






Figure 2.5 ALC25 characterization. (A) IC50 of ALC25 in SPR binding 
assay. (B) PfAtg8 melting temperature in the presence of increasing 
concentrations of ALC25. (C) SPR binding response of PfAtg8 binding to 
Avitag-PfAtg3 peptide in the presence and absence of ALC25. Binding of 
PfAtg8 to the peptide, which binds to the W/L site, is not inhibited by 






Figure 2.6 ALC25 FRED docking report. (A) ALC25 docking pose 
showing four hydrogen bond interactions with PfAtg8. (B) Schematic 
representation of the ligand environment and pocket characteristics, 
showing that most of the ALC25 ligand occupies the A-loop pocket. A 
region near the pyrrolidine ring would allow further extension of the 
ligand. (C) ALC25 had the second-highest docking score of all tested 
compounds in the filtered ChemBridge core library. (D) The residue 
fingerprint highlights residues in proximity to the ligand; residues in bold 
are in contact with the ligand, and are further distinguished by color 
based on the type of interaction. (E) Additional properties for ligand 
optimization guidance are given based on shape, hydrogen bonding 






Figure 2.7 Effect of ALC25 on blood-stage parasite development. 
(A) IC50 of ALC25 and CQ in blood-stage parasites as determined through 
the SYBR green I assay. (B) Western blot: the top section of the western 
blot shows the protein stain, indicating apparent uniform protein loading 
across the lanes. The lower molecular weight range of the gel was probed 
with anti-TgAtg8 antibody, which cross-reacts with PfAtg8. Treatment 
with 100 µM ALC25 for 5 h led to a shift in PfAtg8 mobility, 
corresponding to a shift from a predominantly lipidated (black dotted 
line) to unlipidated (gray dotted line) population. (C) Quantification of 






Figure 2.8 Effect of ALC25 on liver-stage parasite development. 
(A) Flow-cytometry-based detection of P. falciparum 3D7HT-GFP EEFs 
propagated in the presence of ALC25 or DMSO as a vehicle control until 
96 h post-infection. Representative dot plots for each condition are 
shown. Numbers reflect percentages of viable infected cells (GFP+/PI-). 
The bar graph gives the mean (±SD) of EEF percentages from three 
independent hepatocyte cultures. Non-infected and DMSO controls 
previously published [83]. (B) Representative dot plots illustrating 
percentages of viable cells (Annexin V-/PI-) detected by flow cytometry in 
HC-04 cultures treated with ALC25 or DMSO (vehicle control) for 96 h. 







Figure S2.1. ChemBridge Core Library properties. (A) The cLogP 
distribution; (B) the molecular weight distribution; (C) the percentage of 
chiral molecules in the library; and (D) an Omega2 conformer plot 






Figure S2.2. ITC with ALC25. (A) The raw ITC curve and the ∆H from 
integration for a titration of 50 µM ALC25 into 5 µM PfAtg8CM/LD. No 
observable heat of binding between ALC25 and the loop deletion mutant. 
(B) The raw ITC curve and the ∆H from integration for a titration of 
50 µM ALC25 into 5 µM PfAtg8CM. Fits to a one-site binding model. 
(C) Both graphs of ∆H are placed on the same axes for ease of 



























Fit to WT binding
     Fit Parameters
Model: one site binding
Chi^2/DoF=2.659E4
N  = 1.14   ± 0.0504
KB = 1.01E6 ± 2.57E5
∆H = -3449  ± 239.6
∆S = 15.9 
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The following chapter represents predominantly unpublished work. 
However, as the third author on [85], I helped to detect and quantify the 
presence of lipidated and unlipidated PfAtg8 in PTA5-treated, infected 
cells via Western Blot. These images have been reproduced below with 
permission. 
I acknowledge Dr. Hain for her work in the initial screening of the 
MMV library against the PfAtg3-PfAtg8 interaction and subsequent in 
vitro and in vivo measurements, as published in [83]. I also thank the 
laboratory of Dr. Caren Freel-Meyers for the synthesis of PTA4, PTA5, 
and the PTA derivative library. Dr. J. Smith from Seattle BioMed provided 
the FCR3-CSA strain of parasite used in the flow cytometry assay as well 
as the PfEMP1 antibody used in that assay. Dr. J. Levitskaya provided 




The Medicines for Malaria Venture (MMV) Malaria Box of 400 
compounds was tested against the P. falciparum Atg8–Atg3 interaction 
via Surface Plasmon Resonance (SPR), leading to the identification of 
three inhibitory compounds that shared a common scaffold: 4-pyridin-2-
yl-1,3-thiazol-2-amine (PTA). One of these compounds, PTA1, was tested 
in parasite cultures: it had an in vivo IC50 of 1.6 µM and led to a marked 
increase in the level of Atg8 and a shift to a predominantly unlipidated 
population as assayed via Western Blot. Based on these promising 
results, a PTA-derivative library was generated, consisting of 240 unique 
molecules sharing the PTA scaffold. In this work, the library of 
compounds is tested against multiple homologous Atg8–Atg3 interactions 
from the following species: Plasmodium falciparum, Toxoplasma 
gondii/Neospora caninum, Eimeria tenella, and Cryptosporidium parvum. 
This derivative library screening yields numerous potential hits. Using 
the same SPR setup and the same protein homologue pairs, the hits from 
the Virtual Ligand Screening against PfAtg8 are also screened. Finally, 
several PTA-derivative molecules are tested and found to decrease 
infected red blood cell (iRBC) surface-exposed P. falciparum erythrocyte 
membrane protein 1 (PfEMP1) levels. These results are promising for 




The following work is an effort to explore the effects on 
apicomplexan Atg3-Atg8 interactions of two groups of molecules: (1) a 
class of 4-pyridin-2-yl-1,3-thiazol-2-amine (PTA) derivative drugs and (2) 
virtual ligand screening (VLS) hits, both shown to have activity against 
the PfAtg3-PfAtg8 interaction [83,85]. 
As discussed in previous chapters, the autophagy pathway or, 
more specifically, the Atg8-conjugation pathway within apicomplexans is 
a strong candidate for drug development, based on its essentiality within 
investigated species (P. falciparum and T. gondii). The value in targeting 
Atg8 in multiple species simultaneously is that, while each protein target 
is unique, such an approach takes advantage of common features and 
high sequence similarity to potentially identify novel classes of anti-
apicomplexan molecules. 
The identification of a novel antimalarial, in particular, is 
important not only because of increased drug resistance, but also 
because current medications are not as effective in treating severe 
malaria. Cerebral malaria is one manifestation of severe malaria, 
characterized by impaired consciousness. For children, a diagnosis of 
cerebral malaria is a death sentence without treatment; even with it, 20% 
will not survive, and many survivors will suffer long-term neurological 
damage [132]. This form of malaria is linked to the expression of 
Plasmodium falciparum erythrocyte membrane protein 1 (PfEMP1) [133]. 
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PfEMP1 is involved in evading host immunity: the protein is 
exported from the parasitophorous vacuole to knobs on the surface of 
infected red blood cells (iRBCs). PfEMP1 then binds to receptors on 
various host cells, sequestering the infected cells from circulation and 
allowing the iRBCs to avoid clearance by the spleen [134,135]. Because 
PfEMP1 is a major virulence factor, it has been the target of numerous 
studies, and has become an important malaria vaccine candidate [136]. 
Direct targeting of PfEMP1 is complicated by the fact that the malaria 
parasite expresses only one of approximately 60 PfEMP1 variants at any 
given time [137]. An equally viable and perhaps more accessible 
approach would be to inhibit the export of PfEMP1 to the iRBC 
membrane. 
Along these lines, there is reason to believe that PfAtg8 may be 
involved in export to the host cell. As mentioned in Chapter 1, PfAtg8 has 
been found to colocalize with the Maurer’s cleft (MC), an intermediate 
structure involved in the export pathway [71]. Furthermore, PfAtg8 has 
been found to colocalize with PfEMP1 and to partially colocalize with P. 
falciparum skeleton binding protein 1 (PfSBP-1) [138]. PfSBP-1 is 
involved in PfEMP1 export and localizes to the MC [139]. While PfSBP-1 
is one of many proteins exported to the host, it does not contain the 
canonical Plasmodium export element (PEXEL) motif typical of other 
exported proteins, and PfEMP1 is missing a hydrophobic signal sequence 
also characteristic of exported proteins, leaving open questions as to how 
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these proteins make their way to the host. To test the involvement of 
PfAtg8 with this process, we used two of the PTA inhibitors in a flow 




Sequence similarity and homology modeling of PfAtg8 homologues 
confirm feasibility of drug repositioning 
The sequence for Atg8 is well-conserved within the apicomplexan 
phylum. In particular, a multiple sequence alignment of Plasmodium 
falciparum Atg8 with the homologous proteins from Cryptosporidium 
parvum, Eimeria tenella, Neospora caninum, and Toxoplasma gondii 
shows greater than 60% sequence identity between PfAtg8 and each of 
the other molecules (Figure 3.1A). Given that the structure of PfAtg8 is 
known, this level of sequence identity makes these protein sequences 
good candidates for homology modeling. I-TASSER is a protein structure 
and function prediction server supported by the Zhang Lab at the 
University of Michigan [140]. It has received first place ranking in the last 
four Critical Assessment of Techniques for Protein Structure Prediction 
(CASP) events for homology modeling [141–144]. Using this server, the 
structures of CpAtg8, EtAtg8, and Nc/TgAtg8 were generated (Figure 
3.1B). A comparison of these structures shows clear areas of 
conservation, both in the W- and L- sites responsible for binding to Atg3 
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and in the A-site unique to the apicomplexan Atg8 homologues (Figure 
3.1C,D). 
In the following studies, we take advantage of these areas of 
conservation by testing compounds targeted against the PfAtg3-PfAtg8 
interaction against the Atg3-Atg8 interactions of other apicomplexan 
organisms. 
 
VLS compounds tested against homologous Atg8-Atg3 interactions 
for C. parvum, E. tenella, and N. caninum via SPR PPI assay 
As described in Chapter 2, we used our SPR assay to test the effect 
of the VLS compounds against the human and P. falciparum Atg3-Atg8 
protein-protein interactions (Figure 2.4). Using a similar setup, we tested 
the same set of VLS compounds against the Atg3-Atg8 interactions for C. 
parvum, E. tenella, and N. caninum/T. gondii. The results for these three 
inhibition assays are shown in Figure 3.2. 
Compounds 11, 13, and 22 resulted in a significant inhibition of 
the CpAtg3-CpAtg8 protein-protein interaction as compared to the 
control (Figure 3.2A). However, for all Atg8 homologues except 
Plasmodium, some precipitation of the protein Atg8 was observed upon 
addition of compound 13, undermining the apparent efficacy of this 
compound as an inhibitor. 
Compounds 5, 29, and 30 resulted in significant inhibition of the 
EtAtg3-EtAtg8 interaction (Figure 3.2B), and in our SPR assay with 
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NcAtg3 immobilized on the chip and Nc/TgAtg8 flowing over it, 
compounds 5, 11, 13, 16 and 22 all resulted in a decreased response 
(Figure 3.2C). 
 
PTA-derivative library created based on favorable initial findings 
The Medicines for Malaria Venture (MMV) made freely available a 
Malaria Box of 200 drug-like and 200 probe-like molecules known to 
have activity against blood-stage P. falciparum malaria [82]. These 
compounds were previously screened against the PfAtg3-PfAtg8 
interaction in a surface plasmon resonance (SPR) assay, with PfAtg3 
immobilized on a chip and PfAtg8 flown over in the presence of each 
compound [83]. Comparing the inhibited response to the control 
response resulted in the identification of six molecules that produced 
greater than a 25% inhibited response. Of these, three molecules showed 
dose-dependent inhibition and shared the same PTA scaffold: N-(4-
methylphenyl)-4-pyridin-2-yl-1,3-thiazol-2-amine (PTA1), 2- 
methylsulfanyl-N-(4-pyridin-2-yl-1,3-thiazol-2-yl)benzamide (PTA2), and 
2-bromo-N-(4-pyridin-2-yl-1,3-thiazol-2-yl)benzamide (PTA3) (Table 1). 
PTA1 had an IC50 of 18.16 ± 0.25 µM in vitro in SPR and 1.6 ± 1.5 
µM in vivo in parasite culture as tested via a SYBR green I growth 
inhibition assay. Not only was it effective in killing the parasites, but it 
also produced a noticeable shift in PfAtg8 lipidation state – the protein 
band shifted from a predominantly lipidated to a predominantly 
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unlipidated population (Figure 3.3A). This shift was also accompanied by 
a remarkable upregulation of PfAtg8 (Figure 3.3B). The shift in lipidation 
state was expected: inhibition of the PfAtg3-PfAtg8 interaction would 
inhibit the subsequent conjugation of PfAtg8 to PE. As for the 
upregulation, it is possible that the parasite responded to the loss of 
lipidated Atg8 by significantly upregulating production of the protein. 
Based on these results, a PTA-benzaldehyde derivative was 
synthesized with a functional handle for the generation of a library of 
PTA-derivative molecules: 4-formyl-N-(4-pyridin-2-yl-1,3-thiazol-2-yl)- 
benzamide (PTA4) (Table 1). An unreactive version of PTA4, 4-
(Dimethoxymethyl)-N-(4-pyridin-2-yl-1,3-thiazol- 2-yl)benzamide (PTA5), 
was synthesized to test the inhibitory effects of this derivative (Table 1). 
PTA5 had an in vitro IC50 of 2.86 µM in SPR and in vivo IC50 of 1.48 ± 0.6 
µM in a SYBR green assay. 
Thanks to our collaborators in the lab of Dr. Caren Freel-Meyers, 
the PTA-derivative library of 232 molecules was created through 
tethering PTA to a library of aldehydes via a dialkoxyamine linker. The 
set of linkers used to create the library is shown in Figure 3.4. 
 
PTA-derivative library tested against five different homologous 
Atg3-Atg8 interactions via SPR interaction assay 
We used our established SPR interaction assay to test the 
inhibitory effects of the PTA derivatives on the Atg3-Atg8 interaction for 
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human, P. falciparum, C. parvum, E. tenella, and N. caninum/T. gondii 
homologues. In each case, the Atg3 homologue was immobilized on the 
SPR chip, with Atg8 flown over in the presence or absence of PTA 
derivatives at 5 µM concentration. To analyze the data, we made use of 
TSIS plots (see Chapter 2), comparing the human response for each 
analyte on the x-axis to the apicomplexan response on the y-axis (Figure 
3.5). We then identified inhibitors that produced a response more than 
two standard deviations lower than the average inhibited response. 
For the P. falciparum interaction, the inhibited responses were so 
much lower than the control responses at 5 µM that the screen was 
repeated at 0.5 µM in an attempt to isolate the most effective of the 
inhibitors. In this second screen, the following analytes produced a 
significantly decreased SPR response: 42, 43, 44, 45, 46, 47, 48, 49, 123, 
124, 125, 126 (Figure 3.5A).  
For the C. parvum interaction, no analytes produced an SPR 
response more than two standard deviations below the average inhibited 
response (Figure 3.5B). Setting the threshold to 1.5 standard deviations 
yielded only three hits: 130, 156, and 159. Of the apicomplexan Atg8 
homologues, CpAtg8 was the most divergent, which could account for the 
lack of hits. 
In the case of the E. tenella Atg3-Atg8 interaction, analytes 8, 46, 
50, and 55 produced a significantly inhibited response (Figure 3.5C). 
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We were unable to successfully clone TgAtg3 after multiple 
attempts. However, since NcAtg8 and TgAtg8 share 100 percent sequence 
identity, we were able to use NcAtg3 as the binding partner for 
Nc/TgAtg8. Presumably, inhibition of this interaction could have 
implications for both the N. caninum and the T. gondii interactions. In 
this case, for the NcAtg3–Nc/TgAtg8 interaction, analytes 41, 67, 72, 74, 
75, 76, and 80 produced a significantly inhibited response (Figure 3.5D). 
 
PfEMP1 expression on surface of iRBCs decreases in response to 
treatment with PTA1 or PTA5 
If PfAtg8 is involved in exporting proteins to the host cell 
membrane, then interruption of PfAtg8 lipidation may decrease the levels 
of exported proteins; in particular, we were interested in measuring the 
level of PfEMP1 via flow cytometry. As previously mentioned, PfEMP1 is a 
protein with approximately 60 variants encoded by the var multigene 
family, the expression of which is altered to enable the parasite to evade 
detection by the immune system. To be able to probe for PfEMP1, we 
used the P. falciparum FCR3-CSA strain of parasite that had been 
selected for binding to chondroitin sulfate A (CSA), a placental receptor. 
Only one PfEMP1 variant, encoded by the var2csa gene, binds to CSA, 
allowing for the use of specific antibodies raised against this variant. 
Using blood infected with this strain, we treated late ring stage 
parasites with PTA1 or PTA5 at 3 µM and 30 µM concentrations for 16 
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hours. After 16 hours of treatment, we probed for PfEMP1 with rabbit 
antisera raised against var2csa or with control rabbit antisera. The cells 
were then stained with a secondary antibody and with Thermo Fisher® 
DRAQ5TM, a fluorescent DNA intercalator, to differentiate between 
infected and uninfected cells. One million cells were screened for each 
sample.  
We removed clumped or dead cells from consideration by gating 
based on forward and side scatter (Figure 3.6A). To isolate the parasite-
infected cells, we measured DRAQ5 fluorescence, gating conservatively to 
ensure the population under consideration predominantly consisted of 
iRBCs (Figure 3.6B). Based on DRAQ5+ staining, the percentage of iRBCs 
did not substantially differ between the control sample and the samples 
treated with 3 µM of either PTA1 or PTA5. When treated with 30 µM 
PTA1, however, the percentage of infected cells dropped to 50% and for 
30 µM PTA5, it dropped to 73%. 
We compared PfEMP1 staining in the treated samples to the 
PfEMP1-positive population in the DMSO control. In the 3 µM PTA1 
treatment, the percent of iRBCs positively stained for PfEMP1 dropped to 
87.6% and down to 40.3% for 30 µM PTA1 treatment. Treatment with 3 
µM PTA5 did not lead to a decrease in the PfEMP1-positive population, 
but 30 µM PTA5 led to 58.8% PfEMP1-positive staining. 
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Discussion and Future Directions 
The high degree of sequence similarity between the apicomplexan 
Atg8 homologues (Figure 3.1) makes it possible to consider screening 
similar inhibitors against the Atg3-Atg8 protein-protein interaction (PPI) 
for multiple organisms. Furthermore, such an approach has the benefit 
of streamlining further drug development efforts. Identifying a class of 
molecules with inhibitory effects could substantially decrease future 
costs associated with the testing and development of this class. 
From the set of apicomplexan loop compounds (ALCs), in each 
case, several showed significant inhibition of the Atg3-Atg8 PPI (Figure 
3.5). As with the verification of ALC25, the next step would be to 
investigate SPR dose-dependency and then begin in vivo assays. There 
was some difficulty in dose-dependent studies as the ALCs showed only 
limited inhibition and poor solubility, making it difficult to explore a 
range of concentration values. It would be informative in each case to 
take several of the compounds and attempt other in vitro dose 
dependency assays or simple in vivo assays. In general, given that these 
compounds were identified in an in silico screen against the A-loop of 
PfAtg8, it is not surprising that they exhibit weak inhibition of other PPIs. 
In the case of the PTA-derivative molecules, the results were more 
encouraging. Excluding the C. parvum interaction, in each case, there 
were a number of PTA derivatives that produced an inhibited response 
more than two standard deviations below the average inhibited response. 
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This improved inhibitory success rate was to be expected based on the 
higher degree of conservation in the apicomplexan Atg8 W- and L- sites. 
These are the primary interaction sites for Atg3, and the PTA molecules 
are thought to bind here [83]. The variety of linkers featured in the 
library allowed for tailored binding to each molecule. 
The data featured here represents only a preliminary screen of the 
molecules, however. Given more time, the next steps would involve many 
of the assays featured in Chapter 2 and in [83]. In vitro assays would 
include testing for dose dependency via SPR and direct binding via ITC. 
Of course, in each case, crystal structures and co-crystals with bound 
ligand would be informative regarding the binding site and mode of 
inhibition. Assuming further in vitro assays produced encouraging 
results, in vivo testing would be the next step. As in the case for PTA1 
and PTA5, we would expect to see significant inhibition of parasite 
growth with treatment. As is the case for the plasmodial homologue, 
EtAtg8, NcAtg8, and TgAtg8 are synthesized with an exposed C-terminal 
glycine, meaning that they also likely exist in a predominantly lipidated 
state. Given this fact, we would expect to see similar changes in the 
lipidation states of these proteins upon treatment with PTA derivatives. 
Finally, taking a closer look at the effect of the PTA molecules on P. 
falciparum in particular, the results of the PfEMP1 inhibition assay are 
promising. Treatment with PTA1 and PTA5, which have been shown to 
inhibit the interaction between PfAtg8 and PfAtg3, led to a substantial 
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decrease in the level of PfEMP1-positive staining on the surface of iRBCs. 
Based only on these results, it is impossible to know the mode by which 
PTA1 and PTA5 led to PfEMP1 export inhibition, but it is possible that 
this inhibition is the result of the change in PfAtg8 lipidation state.  
To determine the veracity of this claim, in-depth follow up would 
be required. First and foremost, flow cytometry with fixed and 
permeabilized cells would allow us to test the overall levels of PfEMP1 in 
infected cells. These overall levels could also be probed via western blot 
analysis. If the export pathway is being affected, one would not 
necessarily expect to see a decrease in the overall level of PfEMP1 
expression, only in the amount that successfully reached the surface of 
the cell. Immunofluorescence analysis of treated cells would also allow 
us to visually monitor a change in PfEMP1 localization, though this 
technique may not be large-scale enough to definitively detect a 
difference between untreated and treated cells [138].  
 
Materials and Methods 
Multiple sequence alignment and homology modeling. The 
sequences for the proteins in this study were downloaded from 
EuPathDB: P. falciparum Atg8 (EuPathDB gene ID: PF3D7_1019900), C. 
parvum Atg8 (cgd7_3990), E. tenella Atg8 (ETH_00016760), N. 
caninum/T. gondii Atg8 (NCLIV_008410 and TGME49_254120) [39]. The 
multiple sequence alignment was performed and rendered by Clustal 
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Omega [125]. The homology models for CpAtg8, EtAtg8, and Nc/TgAtg8 
were generated using the online I-TASSER server [140]. Each sequence 
was submitted with default parameters and the top scoring model was 
chosen as a representative homology model for each protein. Figure 3.1 
panels B-D were rendered using PyMOL [130] and panels C and D were 
colored based on the color_by_conservation.py script [145]. 
Plasmid and strain construction. The plasmid and strain 
construction for PfAtg8, PfAtg3, hLC3, and hAtg3 is as in [81] and [85]. 
The sequences for CpAtg3, CpAtg8, EtAtg3, and EtAtg8 were determined 
by homology to PfAtg3 or PfAtg8 using the online database EuPathDB 
[39], and then confirmed by sequence homology from BLAST searches. 
These genes were codon-optimized for expression in E. coli and ordered 
as gBlocks® gene fragments from IDT®, with encoded NcoI and BamHI 
restriction sites at the beginning and end of the gene. The gene blocks 
were digested with New England BioLabs® (NEB) NcoI and BamHI 
restriction enzymes and ligated with NEB T4 DNA ligase into a modified 
pRSF vector containing an N-terminal maltose binding protein (MBP) tag 
followed by a tobacco etch virus (TEV) protease cleavage site [86]. These 
plasmids were transformed into chemically competent Escherichia coli 
BL21 strain cells. 
We received the TgAtg8 construct from Anthony Sinai at the 
University of Kentucky College of Medicine. The sequence was PCR 
amplified with primers 5'-CACC ATGC CATC GATT CGCG ACGA AGTG 
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TCC (sense) and 5'-ttac ccca gagt gttc tctg aaga gtat tcca cgta ca 
(antisense). We received N. caninum cDNA from Wesley C. Van Voorhis at 
the University of Washington, Seattle. We retrieved the NcAtg3 sequence 
from EuPathDB [39] (gene id: NCLIV_050410) to design primers, 5’-CATG 
CCAT GGCG CTTC CTCA AAAC G (sense) and 5’-cggg atcc cgct actt ctct 
ttcg tgtg gt (antisense), which we used to PCR amplify the sequence from 
the cDNA. The PCR products for TgAtg8 and NcAtg3 were similarly 
digested and ligated into the MBP-TEV-pRSF vector. This plasmid was 
then transformed into E. coli Rosetta 2 cells.  
Protein expression and purification. For PfAtg8, PfAtg3, and 
hLC3, refer to [81]. For hAtg3, refer to Chapter 2. 
After transformation of each construct, a single colony was 
selected, sequence verified, and then grown in Terrific Broth (TB) media 
with the appropriate antibiotics: 50 µg/mL kanamycin for CpAtg3, 
CpAtg8, EtAtg3, EtAtg8, NcAtg3, and TgAtg8; 34 µg/mL chloramphenicol 
for NcAtg3 and TgAtg8. Growth, induction, harvesting, lysing, and 
clearance were performed as detailed in Chapter 2. 
After lysis and clearance via centrifugation, the supernatant was 
decanted to incubate with NEB amylose resin for 30 min. Resin was 
washed with lysis buffer and then incubated for another 30 min with 
elution buffer: lysis buffer plus 10 mM maltose. The eluted protein was 
collected and then cleaved overnight with TEV protease at a mass ratio of 
1:100, while simultaneously dialyzed into 10 mM HEPES pH 7.5, 100 
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mM NaCL, 1 mM DTT. Cleaved CpAtg8 was not stable in HEPES buffer, 
so this dialysis buffer was 10 mM Tris pH 7.5, instead. After overnight 
cleavage, each protein was separated from MBP and TEV protease by 
anion exchange using a RESOURCETM Q column (GE® Healthcare) on an 
ÄKTATM purifier system. The Atg8 proteins were collected from the RQ 
flowthrough, while the Atg3 proteins were collected from a single peak on 
the chromatogram well-separated from MBP and TEV protease. For SPR, 
proteins were concentrated to 1-3 mg/mL and buffer exchanged into the 
indicated running buffer. 
Immunoblots. See [83]. 
SPR PPI assays. An SPR assay was developed for PfAtg8 and 
PfAtg3 as described previously in [81]. The hAtg3-hLC3 SPR PPI assay 
setup is described in Chapter 2. Based on these assays, we developed 
similar interaction assays for CpAtg3-CpAtg8, EtAtg3-EtAtg8 and NcAtg3-
Nc/TgAtg8 using our standard running buffer: 10 mM Hepes pH 7.5, 150 
mM NaCl, 0.01% Tween 20. All buffers were filtered and degassed for 1 h 
before each experiment. Small molecule inhibitors were stored in 100% 
DMSO at 500 µM and tested at 5 µM concentrations (PTA derivatives) or 
stored at 100 mM and tested at 500 µM concentrations (VLS 
compounds). The inhibition due to VLS ligands was measured in 
triplicate. To maintain a constant ratio of DMSO in all small molecule 
inhibitor assays, the running buffer was supplemented with 1% DMSO. 
All measurements were analyzed with BioLogicTM Scrubber and corrected 
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for DMSO effects using double referencing with interspersed blank 
injections and an untreated flow cell on the SPR chip. To control for 
surface decay, control injections (Atg8 supplemented with DMSO, but no 
small molecule inhibitors) were injected every 12 injections. 
For each Atg3-Atg8 interaction pair, a new CM5 SPR chip was 
used. For all PPI studies, the Atg3 homologue was immobilized, with the 
Atg8 partner passed as an analyte over the chip in the presence of small 
molecule inhibitors or equivalent DMSO. To immobilize Atg3 on the chip, 
we carried out a pH scouting from pH 4.0 to pH 6.0 in 0.5 pH unit 
intervals to determine the best conditions for immobilization. Flow cells 
were activated using N-hydroxysuccinimide (NHS) and 1-ethyl-3-(3-
dimethylaminopropyl)carbodiimide (EDC) for 7 min with a flow rate of 20 
µl/min. For CpAtg3 immobilization, a solution of 50 µg/ml of CpAtg3 in 
10 mM sodium acetate pH 5.0 was passed over one flow cell until >500 
Response Units (RU) were captured. The same procedure was followed for 
the immobilization of EtAtg3 and NcAtg3, with a pH of 5.0 and pH 5.25, 
respectively. To block activated free binding sites, we exposed the flow 
cell to 0.5 M ethanolamine in running buffer for an additional 7 min. For 
the ALCs, the flow rate was 40 µl/min flow rate with a 75 s contact time, 
followed by a 1 minute dissociation time and a 25 µl regeneration 
injection of either 2 M MgCl2 or a mixture of 10 mM NaOH, 10 mM 
HEPES pH 7.5. For the PTA derivatives screening, the same regeneration 
conditions were used, but the flow rate was 50 µL/min, and the contact 
 93 
time was 3 min, followed by 30 s wait time and 20 µL regeneration. Dose-
response curves were then used to determine the approximate 
concentration of analyte to obtain a response of 100-150 RU in the 
absence of ALCs. 
All measurements were carried out on a BiaCore 3000 instrument. 
Flow cytometry. We treated uninfected blood or blood infected 
with P. falciparum FCR3-CSA ring-stage parasites. For each sample, 200 
µL of culture had drug or 100% DMSO added in 1:100 ratio, for a final 
concentration of 1% DMSO in all cases. After 16 h incubation, the 
samples were centrifuged at 500 rcf for 2 minutes, and the supernatant 
was removed. The pelleted cells were resuspended in 200 µL 1xPBS and 
then divided into two tubes (one for primary antibody, one for control 
antibody). The cells were centrifuged again, the supernatant was 
removed, and they were resuspended in 100 µL of rabbit αVar2csa 
antibody (1:25 in 1xPBS, 3% BSA) or 100 µL of control rabbit antisera 
(1:1250 dilution in 1xPBS, 3% BSA) and incubated for 30 minutes at 
room temperature. The samples were then washed 3x with 600 µL 
1xPBS, resuspended in 75 µL Molecular Probes® Alexa Fluor 488 
αRabbit IgG (1:500 dilution in 1xPBS, 3% BSA), and incubated at room 
temperature for 30 minutes. After washing again three times with PBS, 
the samples were resuspended in 1 mL of DRAQ5 dilution (1:5000 in 
1xPBS). 
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Samples were flown through a BD BiosciencesTM FACSCalibur flow 
cytometer at a rate of 5000 events/s until 106 events had been reached 
for each sample. Data was analyzed using FlowJoTM software (Tree Star, 
Inc.). Samples were gated for viable cells based on forward and side 
scatter. Uninfected controls were used to determine the gating for 
infected (DRAQ5+) cells, and the isotype control was used to determine 
PfEMP1+/- gating.  
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Figure 3.1. Apicomplexan Atg8 sequence alignment and homology 
modeling. (A) Sequence alignment of PfAtg8, CpAtg8, EtAtg8, NcAtg8, 
and TgAtg8 produced by Clustal Omega [125]. Colored by side chain. 
Symbols correspond to degree of conservation: “*” indicates identical 
residues for all homologues; “:” indicates high conservation; “.” indicates 
some conservation. Note that NcAtg8 and TgAtg8 are identical.  (B) From 
left to right: the structure of PfAtg8 (in green) followed by the homology 
models for CpAtg8 (cyan), EtAtg8 (magenta), and Nc/TgAtg8 (orange). In 
(A), it is clear that CpAtg8 is missing 18 residues from the N-terminus as 
compared to the other homologues, which accounts for the more limited 
N-terminal helix in the model. (C) The peptide backbone of PfAtg8 colored 
by conservation via the color_by_conservation.py script [145]. Orientation 
of the protein is as in (B). Colors range from red (highly conserved) to 
blue (not conserved) on a rainbow scale and are based on the PyMol 
alignment RMSD. The backbone is highly conserved among the 
homologues. (D) Two surface representations of the structure of PfAtg8, 
including side chains, colored by conservation as in (C). There is a 
greater degree of variability when considering side chains, but a number 







Figure 3.2. Results of VLS compound screen in SPR PPI assay. DMSO 
control responses are in green. Blue indicates a compound that caused 
some precipitation of either drug or protein when added to the protein 
sample. Error bars represent the 95% confidence interval for three 
measurements. Results are shown for the (A) C. parvum, (B) E. tenella, 
and (C) N. caninum Atg8-Atg3 interactions. In (B), the SPR responses in 
the presence of ALC13 and ALC24 are not shown as these compounds 
produced unreliable SPR responses likely due to precipitation.  





Figure 3.3. Western blots demonstrating change in PfAtg8 lipidation 
state and expression level upon treatment with PTA1. (A) Treatment 
with varying levels of PTA1 led to a shift from lipidated to unlipidated 
PfAtg8. (B) Treatment with 50 µM PTA1 for five hours led to a substantial 




Figure 3.4. PTA-derivative library linkers 
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Figure 3.5. Results of PTA derivative library screen in SPR PPI 
assay. The SPR response in the presence of each analyte is plotted for 
both human (x-axis) and apicomplexan (y-axis) Atg8-Atg3 interactions. 
All responses within two standard deviations of the average response are 
enclosed in a black rectangle. Potential inhibitors are colored red and 
enclosed in the green rectangle, representing analytes that don’t 
significantly affect the the human interaction but produce a significant 
reduction in the SPR response for the apicomplexan interaction. The 
results are shown for (A) the P. falciparum Atg8-Atg3 interaction with the 
PTA derivatives tested at 0.5 µM and (B) the C. parvum, (C) E. tenella, 
and (D) N. caninum Atg8-Atg3 interactions with the derivative library 







Figure 3.6. Flow cytometry analysis of PfEMP1 levels in treated vs 
untreated iRBCs. (A) An example dot plot illustrating the gating used to 
select viable single cells based on forward (x-axis) and side (y-axis) 
scatter. (B) An example dot plot illustrating the gating for DRAQ5+ 
(infected) cells. (C) The isotype control (magenta) and the infected, 
untreated control were used to determine PfEMP1+/- gating. For viable, 
infected cells, levels of PfEMP1 differed between the cells that were left 


















The parasitic protists of the phylum, Apicomplexa, represent an 
area of active research. Chapter 1 gives a broad overview of this phylum 
and what is currently known about apicomplexan autophagy. From the 
research that has been conducted so far, it appears that these parasites 
have co-opted the autophagy pathway to serve novel purposes unique to 
the parasite lifecycle; for example, Atg8 localizes to the apicoplast, an 
organelle that does not exist in higher level eukaryotes. Also in this 
chapter, the opportunity to target the Atg3-Atg8 protein-protein 
interaction (PPI) within apicomplexans in general and within Plasmodium 
specifically is discussed in detail. In both P. falciparum and T. gondii, 
Atg8 has been found to be essential. In addition, the structure of PfAtg8 
is known and reveals an apicomplexan loop (A-loop) that represents a 
point of divergence from human Atg8 homologues but is conserved in 
Apicomplexa. 
Chapter 2 presents the results of targeting this A-loop in a recent 
virtual ligand screening (VLS) conducted against the A-loop pocket in 
PfAtg8. From this screen, apicomplexan loop compound 25 (ALC25) 
showed dose dependent inhibition of the PfAtg3-PfAtg8 PPI in SPR with 
an IC50 of 18.5 µM and had a similar in vivo IC50 of 19 µM in a SYBR 
green I assay. ALC25 inhibition also produced a shift in PfAtg8 lipidation 
and an upregulation of PfAtg8 production, as had previously been shown 
for another PfAtg3-PfAtg8 PPI inhibitor [83]. Our follow-up SPR and ITC 
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experiments confirmed that ALC25 does not bind to the W- or L-sites and 
furthermore does not bind to the loop deletion mutant of PfAtg8. These 
results taken together point to ALC25 inhibiting parasite growth by 
binding to the A-loop pocket of PfAtg8, disrupting the Atg3-Atg8 PPI, 
proving that this is a viable approach to drug development against P. 
falciparum. 
Finally, in Chapter 3, I present the unpublished results of our 
efforts to target apicomplexan Atg3-Atg8 interactions with two classes of 
ligands targeting the PfAtg3-PfAtg8 interaction. From these screens, we 
identify a number of potential hits inhibiting each of the homologous 
Atg3-Atg8 interactions: P. falciparum, C. parvum, E. tenella, N. 
caninum/T. gondii. In this chapter, also discussed are the exciting results 
of our PfEMP1 flow cytometry assay, in which inhibitors of the PfAtg8-
PfAtg3 PPI lead to an overall decrease in the level of surface-exposed 
PfEMP1, a major virulence factor. 
 
Future directions and remaining questions 
While a number of studies have been conducted to determine the 
roles of TgAtg8 and PfAtg8, many questions remain. Recent studies have 
explored the functions of these proteins in the parasite lifecycle, finding 
evidence for a wide variety of roles (see Chapter 1). Though the 
apicomplexan life cycle and Atg8 sequence similarities suggest that this 
protein may also play a significant role in other apicomplexans, its 
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function has not yet been investigated outside of Plasmodium and 
Toxoplasma. Verification of the hits pursued in Chapter 3, which show 
preliminary inhibition of the Atg3-Atg8 PPI in C. parvum, E. tenella, and 
N. caninum, may provide useful tools for investigating the importance of 
the Atg8 conjugation pathway in some of these organisms. If Atg8 
essentiality holds in these species as well, there is great potential for a 
novel class of anti-apicomplexan therapeutics among the PTA-derivative 
molecules. 
Of great significance as well are the results of the PfEMP1 flow 
cytometry experiment implying a role for PfAtg8 in export to the host cell. 
As discussed in Chapter 3, however, more work needs to be done to 
explore this connection. Better co-localization immunofluorescence 
assays may be possible with higher resolution techniques and more 
specific antibodies, as we now have an antibody directly targeted against 
PfAtg8, versus the less specific TgAtg8 antibody that had previously been 
used. Additionally, flow cytometry and western blot analysis of global 
expression levels of PfEMP1 would answer important questions about the 
mode by which PTA1 and PTA5 reduce surface-level expression of the 
protein. If PfAtg8 is, indeed, involved in export of PfEMP1 to the host, 
then inhibitors of the Atg3-Atg8 PPI would have important implications 
for severe, cerebral malaria. 
Finally, based on the work presented here, an important potential 
area of lead development is the linking of the two classes of molecules 
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explored in this thesis. Our data support the hypothesis that ALC25 is 
indeed binding to the A-loop pocket as its primary mode of inhibition, 
while the PTA derivatives are thought to bind to the W- and L-sites. To 
take advantage of the tighter binding of the PTA derivatives, but improve 
specificity for the plasmodial target, it may be possible to connect the 
molecules with a variety of linkers, allowing for a drug that took 
advantage of both sites. To probe the feasibility of such an endeavor, we 
could conduct SPR PPI assays using both drugs to determine if they 
inhibit synergistically or antagonistically. In general, drug development 
efforts would be enhanced by the solution of ligand-bound crystal 
structures. 
 
Developing cost-effective anti-apicomplexan therapeutics 
Recent years have seen an increase in malaria funding globally and 
a corresponding decline in rates of infection and mortality [146]. Infection 
prevalence in endemic Africa, in particular, has halved over the last 
decade [3], giving great hope for the possibility of malaria eradication. 
While this trend is encouraging, we must be realistic in facing remaining 
challenges. Malaria is still a serious threat, and many figures regarding 
global malaria mortality may be underestimated: by some measures, the 
current rates of death as a result of malaria infection are still likely to be 
above one million per year [147]. Additionally, in comparison to its 
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impact on global health, malaria is still underfunded, especially when 
compared to diseases such as cancer, for example. 
Furthermore, as discussed in previous chapters, the supply of 
effective antimalarials is steadily dwindling. For many other 
apicomplexan diseases, the arsenal of available therapeutics is even 
more limited, nonspecific, or toxic [33,148]. Such realities highlight the 
need for new effective medication, both in treating malaria and in 
confronting other apicomplexan ailments. 
Unfortunately, for diseases like malaria that predominantly affect 
citizens of developing nations, there is little incentive for pharmaceutical 
companies to invest in research and development when there is no 
assurance of long-term profits. The pharmaceutical industry often takes 
a high-throughput screening approach to drug development, 
synthesizing and testing impressively large libraries of potential drugs 
[149]. These screens are conducted in the hopes of discovering a hit that 
can then be marketed at a price to recuperate the enormous expense of 
the discovery process, now estimated to be over US$2 billion [150]. Such 
an approach relies on the profits from successful drugs to compensate 
for the expense of failed leads [150,151]. Inherent to this equation is the 
assumption of a wealthy target population. However, for diseases like 
malaria, there is no guarantee that those who suffer from it will be able 
to foot the bill. 
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Because of this challenge and the general difficulty in producing 
new drugs [152], there is significant appeal for the methods featured in 
this thesis – namely, VLS, the MMV Malaria Box, and screening against 
the Atg3-Atg8 PPI in multiple organisms with related compounds. In 
certain situations, VLS alone has the potential to reduce drug 
development costs by up to 50% in the long run [153]. Similarly, the 
Malaria Box can substantially lower long-term costs by providing 
researchers with a known starting place: each of the compounds in the 
screen has confirmed activity against blood-stage P. falciparum and is 
commercially available [154]. 
Finally, the ability to target multiple Atg3-Atg8 PPIs with one class 
of molecules is desirable on multiple levels. Recent years have seen an 
increasing awareness of the value of drug repositioning [155]. Wherever it 
is possible, drug repositioning represents a significantly cheaper 
alternative to the traditional drug discovery process. Along the same 
lines, drug development of a class of molecules targeting multiple 
apicomplexan PPIs would limit the inherent expense of the drug 
development process. It could also allow for the potential treatment of 
multiple zoonotic infections simultaneously, an approach that is already 













The field of crystallography has seen many (now notorious) 
examples of flawed, wildly inaccurate, or completely fake crystal 
structures (see [157] for early examples, [158] and [159] for more recent 
examples). Luckily, with the advent and increased utility of numerous 
crystallographic validation tools, the modern crystallographer is more or 
less saved from such a fate. High free R factors, poor geometry, 
anomalous Ramachandran plots, numerous steric clashes, and bad 
rotamers, among other features, sound the alert as to possible problems. 
Many of these validation checks are automated into the refinement 
process, allowing even beginners to reliably check the quality of their 
structure, though the odd persevering researchers may still find their 
way down the rabbit hole, as in [158]. The following description of a 
failed crystallographic effort is in a way a testament to this, as the false 
structure never made it past the refinement stage due to abnormal 
crystal contacts, poor geometry and a consistently high free R-factor. 
Nevertheless, many of the other best practices of crystallography were 
not followed, practices that might have prevented many wasted hours 
spent in fruitless attempts at structure solution. Hence, for the purposes 
of self-edification and as a cautionary tale for other graduate students, 
the details of this effort and possible precautions that could have been 
followed have been included herein. 
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Materials, Methods, & Possible Precautions 
Strains & Growing Conditions. The details for the constructs and 
growing conditions for CpAtg8, EtAtg8, and TgAtg8 are listed in Chapter 
3. In summary, all three proteins were encoded on a modified pRSF 
vector with an N-terminal Maltose Binding Protein (MBP) followed by a 
Tobacco Etch Virus (TEV) cleavage site. CpAtg8 and EtAtg8 were 
expressed in BL21 E. coli cells and TgAtg8 was expressed in Rosetta 2 
cells. They were grown in Terrific Broth (TB) at 37°C to an OD600 of 3 and 
then induced with 0.5 mM IPTG and grown overnight at 20°C. 
Purification of MBP fusion proteins. After harvesting, lysis, and 
clearance (see chapters 2 and 3), the cleared lysate was incubated with 
New England Biolabs® amylose resin for 30 minutes. The flowthrough 
was collected (flowthrough – Figure A.1A,#1) and then the beads were 
washed with lysis buffer (10 mM HEPES pH 7.5, 150 mM NaCl, 1 mM 
DTT) (wash – Figure A.1A,#2). Bound Atg8 protein was incubated with 
lysis buffer plus 10 mM maltose for 30 minutes and then collected 
(elution – Figure A.1A,#3-6). This eluted protein was pooled and cleaved 
overnight at 4°C with TEV protease at a 1:100 mass ratio (cleaved protein 
– Figure A.1B,#1) and dialyzed into Buffer A: 10 mM HEPES pH 7.5 (Tris 
pH 7.5 for CpAtg8), 75 mM NaCl, 1 mM DTT. 
The Atg8 protein was separated from MBP and TEV protease via 
anion exchange using a GE® Healthcare RESOURCETM Q column, using 
a gradient to elute various proteins going from the low salt Buffer A 
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condition to the high salt Buffer B: 10 mM HEPES pH 7.5 (Tris pH 7.5 for 
CpAtg8), 1 M NaCl, 1 mM DTT. The Atg8 proteins have high isoelectric 
points, around or above pH 8, so they were not negatively charged at a 
pH of 7.5. This means that they did not bind to the Q column, and were 
instead collected from the flow-through coming through the column 
(Figure A.1C,D#1-3). MBP and TEV protease did predominantly bind to 
the column and were eluted in later peaks (Figure A.1C,D#5-10).  
Precautions. While Figure A.1 suggests that the Atg8 protein was 
reasonably pure before being set in crystal trays, the purity of the Atg8 
proteins varied between preps. A solution to this impurity, and 
specifically contamination with MBP, would be to add an additional 
purification step. Early efforts to use size exclusion chromatography to 
this effect were unsuccessful, as it consistently co-eluted with MBP, 
likely because of Atg8 dimerization. However, there are other ways to 
improve purity, including hydrophobic interaction chromatography, 
repeated ion exchange chromatography, additional affinity tag 
chromatography (through the addition of an N-terminal His-tag for 
example), along with many others. A simple starting point can be found 
in [160], which provides a number of successful strategies used by 
structural genomics centers to crystallize proteins. For a simple listing of 
possible purifications strategies, consider the GE® Healthcare Strategies 
for Protein Purification Handbook or, for more depth, consider a textbook 
such as [161]. 
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Setting crystal trays. The protein collected from the flowthrough 
of the anion exchange was concentrated to approximately 5 mg/mL, until 
protein aggregate was noted. The concentrated protein was then 
centrifuged at 18000 g to remove protein aggregates. These proteins were 
then set in 3x96-well sitting drops using a variety of crystallographic 
screens at a 2:1 ratio, 400 nL of protein and 200 nL of crystal reservoir. 
The top drop had CpAtg8, the middle drop had EtAtg8, and the bottom 
drop had TgAtg8. 
Crystals. From the initial screens, crystal formation was noted in 
the Jena Bioscience JBScreen Classic blocks from the reservoir condition 
that contained 100 mM Tris pH 8.5, 0.2 M MgCl2, 30% w/v PEG-4000 
(Figure A.2A). This crystallization was reproduced at pH values varying 
from 7 to 8, PEG-4000 or PEG-3350 concentrations varying from 25% to 
35%, and with various additives in 4x24 sitting well formats. All of the 
crystals were plate-like and had some mosaicity, but were untwinned. 
Precautions. Very simply, the crystals could have been run on SDS-
PAGE (even after being shot) and thus discriminated based on the 
protein bands that appeared on the gel. For a simple description, see 
e.g., http://proteincrystallography.org/ccp4bb/message35357.html  
Data collection, indexing and processing. The crystals from the 
initial screen were shot at Brookhaven National Laboratories, using 
iMosflm for the data collection strategy. The diffraction data were indexed 
and processed using XDS [162] via XDSGUI. The crystals were identified 
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via XDS and Pointless to be in space group 19, P212121, orthorhombic 
with unit cell dimensions approximately: 48.72 ÅÍ57.66 ÅÍ123.20 Å. 
Some of the crystals out of the initial screen had sub 2 Å resolution 
according to the XSCALE data summary (Figure A.2B). Analyzing the 
Matthew’s coefficient for one of the “EtAtg8” crystals with CCP4’s 
Matthew_coef yielded: for two EtATg8 molecules in the asymmetric unit 
(ASU), a coefficient of 3.02, solvent content of 59.3%, and probability of 
40%; for three molecules in the ASU, a coefficient of 2.02, solvent content 
of 39.0%, and probability of 59%. 
Precautions. The Matthew’s coefficient for MBP was 1.99 for one 
molecule in the ASU, with a solvent content of 38.36%, and a probability 
of 100% as no other configurations were possible given the unit cell 
dimensions. Thus, an analysis of the Matthew’s coefficient alone was not 
enough to decisively rule out either the Atg8 homologue or MBP. 
Molecular Replacement. After data processing, all efforts to use 
molecular replacement failed or produced dubious results. All three 
homologues (CpAtg8, EtAtg8, and Nc/TgAtg8) have greater than 60% 
sequence identity with PfAtg8 (Figure 3.1A), making any crystal 
structures of these proteins good candidates for molecular replacement 
with the known structure of PfAtg8. However, all attempts at molecular 
replacement with Phenix Phaser-MR simply never finished, as it 
continued to search for solutions meeting certain criteria and failed to 
find any. CCP4’s MolRep produced solutions, but with a Contrast of less 
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than 3, a wRfac of 1 or greater, and a Score of 0.1-0.3, all of which point 
to the solution being false. Molecular replacement was also attempted 
using the same homology models as in Chapter 3, but similarly failed or 
produced weak results. 
Precautions. Once molecular replacement had failed with the PfAtg8 
structure and the other homology-modeled structures, the next logical 
step would have been to attempt molecular replacement with likely 
contaminants such as MBP and TEV protease. In fact, this is how the 
mistake was eventually discovered. 
Refinement. Some of the more plausible solutions from the EtAtg8 
molecular replacement via MolRep were run through rigid body 
refinement and real space refinement using CCP4’s Refmac5 and further 
refinement with phenix.refine. But inevitably, the Rfree value would get 
stuck. In the case where refinement was taken the furthest, the Rwork got 
down to 0.25, but the free R factor was stuck above 0.38. In every case, 
visual inspection of the solution would reveal unnatural crystal packing: 
either the molecules overlapped or there were large empty planes devoid 
of molecules. Additionally, the validation tools available through Coot 
and Phenix consistently produced uninspiring results. 
Precautions. By its very nature, the free R factor (Rfree) serves as a 
precaution against finding your signal in the noise. To give a brief 
overview, the R factor is defined as 𝑅 = ∑| |
∑| |
, where the Fobs values 
are the observed structure factor amplitudes and the Fcalc’s are the 
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structure factor amplitudes derived from the model. Essentially, the R 
factor is a measure of agreement between the observed data and the data 
calculated based on the model. 
However, in protein crystal structure refinement, there are many 
more fitting parameters than observations, leading to the possibility of 
overfitting, in which your model does not represent the structure that 
generated the data but nevertheless accurately reproduces the 
observations. A simple way to detect overfitting is to check the predictive 
power of your model: leave out 5% of your reflections when generating 
your model and then check to see if your model accurately predicts this 
excluded data. This is precisely what the Rfree is. The equation is the 
same as for the R factor, but the Fobs values are structure factor 
amplitudes for a random subset of reflections that have been left out of 
the refinement process. When your model is gradually tweaked to fit the 
data, instead of generated from the data, it will result in a high Rfree: your 
model will fail to be predictive of the reflections that were left out of the 
refinement process. This value is compared to the R factor for the 
reflections that were used in calculating the model, called the Rwork. 
In this case, the model did not accurately describe the data. While 
other problems with the diffraction data can lead to a problem with the 
Rfree, a high Rfree is a classic symptom of an incorrect model. The high 
Rfree combined with clearly incorrect crystal contacts points toward 
obvious problems with the model. 
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Further efforts. Because of the high resolution and the possible 
solutions, I continued to try to refine the model, assuming the problems 
arose from undetected twinning or other impenetrable molecular 
replacement issues. I was encouraged in these efforts by some favorable 
preliminary electron density maps (Figure A.2C). 
MBP solution. After a certain amount of time, however, it became 
clear that nothing was working. As a result, I backtracked through my 
efforts and attempted molecular replacement with MBP, at which point 
the actual solution became easily apparent. Molecular replacement 
results were definitive and after only two rounds of refinement through 
Phenix.refine, the Rwork and Rfree values were 21% and 25%, respectively. 
 
Conclusion 
Crystallography can be a taxing and time-consuming endeavor. 
This process can be made easier by observing best practices or more 
difficult by circumventing these checks in an effort to save time. In the 
end, however, performing the necessary tests to ensure the reality of 
what you are investigating can save much wasted time. I hope the above 
guide provides examples of how to avoid the problems that I faced.  
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Figures 
Figure A.1. Example CpAtg8 purification. (A) A gel showing the 
flowthrough from binding to amylose resin (lane 1), the buffer wash of 
the amylose resin (lane 2), and the maltose elutions (lanes 3-6) from a 
CpAtg8 purification. The ladder in lane 7 is the Biorad Color Plus 
Prestained Protein Ladder. (B) Lane 1 shows the cleavage efficiency after 
overnight TEV protease cleavage of the MBP-TEV-CpAtg8 construct. Lane 
2 – ladder. (C) The chromatogram from the anion exchange. The blue 
curve (280 nm absorbance) shows where protein is eluted from the 
column; the red curve (260 nm absorbance) shows a peak in DNA elution 
in fractions D5-E2; green is the concentration of the high salt buffer B 
(from 0-100%); brown shows the conductivity – the actual concentration 
of salt lags behind the green curve. Stars correspond to fractions run on 
the gel in (D). (D) Lanes 1-3 correspond to the flowthrough, containing 
predominantly cleaved CpAtg8 – fractions B12, B6, and B1. Lane 4 is the 
ladder. Lanes 5-10 correspond to the protein peaks that elute off of the 






Figure A.2. MBP crystal details. (A) Plate-like clusters from initial 
screen. (B) XSCALE summary of crystal statistics in each resolution 
range. Based on CC1/2 values, there is significant data down to a 
resolution of 1.6 Å; based on an I/sigma cutoff of 0.5, there is significant 
data down to 1.69 Å. However, the completeness is limited in these 
resolution shells, and becomes more reliable at around 1.8 Å. (C) Initial 



















DNA topoisomerases solve important topological problems 
resulting from a variety of DNA transactions [163,164]. Type IIA 
topoisomerases (TOP2s), in particular, regulate DNA topology by passing 
one segment (the T-segment) of DNA through a transient double strand 
break in another segment (the G-segment) (Figure B1.A) [165,166]. This 
action allows the enzyme to relax superhelical tension and disentangle 
chromosomal segments [167]. The enzyme, which is a homodimer in 
eukaryotes, accomplishes this complex operation through the 
coordinated motion of dimerizing subunits [168–170]. The dimer 
interfaces make up three “gates:” the N-gate, the DNA gate, and the C-
gate (Figure B.1A,B) [163]. 
Because of the essential role TOP2s play in DNA maintenance and 
cell division, inhibitors of these enzymes are important antibacterial and 
anticancer agents [171,172]. ICRF-187, also known as dexrazoxane, is a 
known inhibitor of eukaryotic TOP2s [173,174]. In particular, its ability 
to bind the alpha isoform in humans (hTOP2A) makes it relevant to 
cancer treatment. There are two TOP2 isoforms in humans – alpha and 
beta (hTOP2B) – which have differential expression throughout the body, 
with hTOP2A being overexpressed in tumor cells [175,176]. 
A crystal structure of dexrazoxane bound to Saccharomyces 
cerevisiae TOP2 (ScTOP2) was solved to 1.9Å resolution, revealing its 
mode of inhibition [177]. Dexrazoxane binds to the interface between the 
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two lobes of the ATPase domain, the N-gate, trapping the molecule in a 
closed state and preventing the overturn of ATP molecules necessary for 
the function of the protein (Figure B.1B). 
While dexrazoxane is a useful tool in probing TOP2 function, it has 
limited efficacy as an anti-cancer drug due to its high (µM) in vivo IC50 
[178]. Additionally, it is not known whether dexrazoxane preferentially 
binds hTOP2A over hTOP2B. Inhibition of hTOP2B can result in off-
target effects, including cardiotoxicity and secondary malignancies 
[171,179,180]. 
Because there is room for improvement, this represents a case for 
which virtual ligand screening (VLS) is an attractive option; specifically, 
the target structure is known and has been solved with a bound ligand. 
This provides a starting location for virtual docking and an initial 
structure for use in enriching a docking library. To maximize the 
likelihood of identifying positive hits, three diverse docking programs 
were used in an initial docking to identify the best program for this 
target: Schrödinger® Glide, OpenEyeTM Fred, and AutoDockTM Vina. 
The following work details the efforts to identify novel ligands 





1QZR selected as target structure, prepared for docking 
There are several structures of eukaryotic TOP2 in the protein data 
bank (PDB), but only five of the ATPase domain. These include two 
crystal structures from yeast (PDB ID: 1PVG and 1QZR) and three from 
human (PDB ID: 1ZXM, 1ZXN and 4R1F). 1QZR, solved to 1.9 Å, features 
the ATPase domain of ScTOP2 bound to dexrazoxane, and is the only 
structure crystallized with a bound inhibitor. 1PVG is the apo structure 
of the same construct. 
A comparison of 1QZR to the human structure 1ZXM, solved to 
1.87 Å resolution, reveals a nearly identical dexrazoxane binding pocket 
(Figure B.1C), validating the use of the ScTOP2 structure as a proxy for 
the human homologue. To determine whether to use the apo or holo 
structure, the binding pockets were compared. The OpenEyeTM 
make_receptor program probes for the shape of a binding pocket and 
determines the volume of this shape. The location in which dexrazoxane 
binds is a relatively small, enclosed binding pocket. A comparison of the 
apo and holo structures revealed an increase in the size of the pocket as 
a result of dexrazoxane binding (Figure B.1D) and a displacement of 
surrounding water molecules. Based on these results, the holo structure, 
1QZR was chosen as the target structure for the VLS. It was then 
prepared for docking in three different docking programs with the 
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Schrödinger® Protein Preparation Wizard, MGLTools, and OpenEyeTM 
make_receptor. 
 
Initial VLS with enriched ChemBridgeTM Express Library identifies 
Schrödinger® Glide as best docking program for ScTOP2 
The ChemBridgeTM Express Library (www.chembridge.com) was 
chosen for the VLS based on its size, diversity, druglike qualities, and 
commercial availability. The library has over 460,000 compounds 
covering a diverse chemical space. The characteristics of dexrazoxane, as 
a known binder, were used to enrich this library via the OpenEyeTM 
ROCS program, which filters compounds based on shape similarity. In 
certain cases, shape-screening alone can outperform traditional docking, 
making it an attractive step in a docking workflow [181]. The top 104 
similar compounds were then prepared for docking through 
Schrödinger’s LigPrep and OpenEyeTM’s OMEGA. 
Using the prepared target protein structure, 1QZR, and the 
enriched ChemBridgeTM Express Library, an initial VLS was conducted 
using Schrödinger® Glide, OpenEyeTM fred, and AutoDockTM Vina, all set 
to run in medium precision mode. 
While the use of a consensus score can outperform a single scoring 
function [182], the more common strategy is to find the program that 
produces the best results for the specific target in question, as no single 
docking program consistently outperforms the others [183]. Typically, 
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this choice is made based on the program’s ability to distinguish between 
hits and decoys in terms of docking rank: generally speaking, the hits 
should be well-ranked and the decoys should be poorly ranked. 
In this case, only the ranking of ICRF-187 was used to determine 
which program best reproduced known binding results, as this is the 
only hit to have been crystallized in the binding site. Comparing the three 
programs’ results, only Glide produced dexrazoxane as a hit within the 
top 100 hits, scoring 6th overall. For Vina, the top ranking ICRF-187 pose 
was ranked 267th, and for OpenEye, this rank was 658. Based on the 
promising results from the standard precision Glide screening, a more 
exhaustive screening was then conducted with Glide in extra-precision 
(XP) mode. 
 
27 compounds selected from GlideXP tested for TOP2 inhibition via 
coupled ATPase assays 
Using the more exhaustive GlideXP, the top scoring pose of 
dexrazoxane was ranked 3rd overall, further verifying that Glide’s scoring 
function correctly selected for a known hit. For in vitro testing, 27 
compounds were selected from the top 100 unique hits. Molecules were 
filtered out based on poor solubility, non-druglike moieties, and 
instability. Table 1 shows the compounds selected for screening. 
These compounds were then tested in vitro against both ScTOP2 
and hTOP2A using an NADH-coupled ATPase assay. In this assay, the 
 132 
consumption of ATP is directly correlated to the oxidation of NADH and 
the resultant loss of 340 nm fluorescence [184]. Thus ATPase activity is 
measured by the slope in the 340 nm absorbance reading. Based on 
these measurements, the IC50 for dexrazoxane against ScTOP2 was 
around 50 µM, while it was much more effective against hTOP2A with an 
IC50 of approximately 1 µM (Figure B.2). 
Against the yeast target, the VLS compounds were ineffective in 
reducing ATPase activity (results not shown), but against the human 
homologue, they showed some inhibitory effect. While these results need 
to be repeated, several of the compounds showed some inhibition of 
hTOP2A ATPase activity at 5 and 50 µM concentrations (Figure B.3). 
 
Future Directions 
It is encouraging to see some measureable inhibitory activity from 
a number of the VLS compounds against the human target, hTOP2A. In 
virtual screening, it is not uncommon for initial hits to show limited 
inhibition. These initial compounds can then act as the basis for further 
lead optimization. Future directions would include developing a structure 
activity relationship (SAR), improved or constrained docking using 
information from these tested hits, and derivatization of initial leads to 




Materials & Methods 
Target selection. A comparison of the structure of ScTOP2 (PDB 
ID: 1QZR) with bound ICRF-187 to the apo structure of ScTOP2 (PDB ID: 
1PVG) using the binding shape detection of OpenEyeTM make_receptor 
led to the selection of 1QZR as the target structure, based on the cavity 
size: 748 Å3 for 1QZR vs 518 Å3 for 1PVG. The human and yeast 
structures, 1ZXM and 1QZR, respectively, were compared in PyMol using 
the color_by_conservation.py script [145]. 
Target preparation. The target was prepared with the 
Schrödinger® Protein Preparation Wizard, using the default values. This 
preparation removed bound waters, added hydrogens, optimized 
protonation states, flipped residues, and optimized the hydrogen bond 
network, among other functions. This prepared structure was then used 
to generate a grid for docking with Schrödinger® Glide, using the ligand 
to define the centroid of the docking volume. No constraints were chosen 
and no volumes were excluded. Six residues were chosen to be rotatable 
groups in the Glide docking: Thr27, Tyr28, and Tyr144 on both chains.  
For use in AutoDockTM Vina, the Schrödinger® prepared protein 
was exported as a PDB file, imported into MGLTools (Scripps Research 
Institute®), processed to leave only polar hydrogens, stripped of the 
bound ligand, and then exported in pdbqt format. The docking volume 
was centered at (27.5, 33, 32.5), with a length of 13 Å in each dimension. 
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For use in OpenEyeTM, the prepared protein was imported into 
make_receptor, and the ligand was chosen to define the docking volume. 
The docking box was chosen to be 1490 Å3, while the detected docking 
shape volume was 793 Å3. 
Ligand preparation. The ChemBridgeTM Express library was 
filtered through Schrödinger® qikprop to eliminate non-druglike 
molecules. The next filtering step was accomplished with OpenEyeTM 
ROCS: the top 10k compounds were selected based on dexrazoxane 
shape similarity. This filtered library was then put through LigPrep with 
default settings to desalt, generate tautomers, vary chiral centers, 
generate possible ionization states at pH values between 2 and 7 (via 
Epik), and minimize resulting structures using the OPLS_2005 force 
field. For OpenEyeTM, this prepared library was run through OMEGA to 
generate conformers, with a maximum of 2000 conformers per ligand. 
For Vina, each of these structures was converted to pdbqt format. 
Docking. Using the prepared 1QZR structure and the prepared 
ligand library, all three programs were initially run in medium precision 
mode. Glide was run using Standard Precision (SP); AutoDockTM Vina 
was run with the exhaustiveness set to 4; and OpenEyeTM was run with 
the Standard resolution for the exhaustive search, 1 Å translational step 
size, 1.5 Å rotational step size. AutoDockTM Vina is a script for docking 
one ligand into a target receptor. To adapt this to screening an entire 
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ligand library, several bash scripts were used (Programs 1,2). For both 
Glide dockings, the settings were left at their default values. 
Constructs and Protein preparation. Both full-length TOP2 
proteins were encoded on a 12Ura-B plasmid with a GAL1 promoter from 
MacroLab (http://qb3.berkeley.edu/qb3/macrolab/) with an N-terminal 
His6 affinity tag followed by a tobacco etch virus (TEV) protease cleavage 
site. Both hTOP2A and ScTOP2 were expressed in the S. cerevisiae 
BCY123 strain and purified via His-tag affinity chromatography and gel 
filtration chromatography, as in [170]. 
ATPase assays. The NADH-coupled reaction mixture contained a 
final concentration of 3.75 mM phosphoenolpyruvate (Sigma-Aldrich®), 
4% v/v pyruvate kinase/lactic dehydrogenase enzyme mixture (Sigma-
Aldrich®), 0.06 mg/mL BSA, 40 mM Tris pH 7.9, 3 mM TCEP, 10 mM 
MgCl2, 0.132 mg/mL sheared salmon sperm DNA, 1% DMSO, 200 µM 
NADH, 100 nM TOP2 (yeast or human A isoform), and 5% glycerol. This 
mixture equilibrated at 30°C (ScTOP2) or 37°C (hTOP2A) for five minutes 
before the addition of ATP, for a final concentration of 4 mM ATP. For 
each condition, NADH fluorescence was monitored every 30 seconds for 2 
h with a CLARIOstar® plate reader (BMG LABTECH). This raw 
fluorescence data was processed in MATLAB® to determine ATP 
consumption (M/s) (Programs 3-9). IC50 measurements were made with 
an adapted program from [185] (Program 8). 
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Tables 
Table B.1: VLS compounds targeting eukaryotic TOP2 




yl)propyl]piperazine-­‐2,6-­‐dione   71384 
  







218.2   -­0.27  
2  
2-­‐(3,5-­‐dimethylpyridin-­‐1-­‐ium-­‐1-­‐yl)-­‐1-­‐
phenylethanone;bromide   2840993  
  
306.2   2.15  
3  
[1-­‐[(E)-­‐3-­‐(2-­‐nitrophenyl)prop-­‐2-­‐
enyl]pyrrolidin-­‐2-­‐yl]methanol   5721669  
  
262.3   2.22  
4  
3-­‐[(4-­‐hydroxyanilino)methylene]-­‐2,4-­‐
pyrrolidinedione   45927571  
  
210.4   3.17  
5  
N-­‐(cyclohex-­‐3-­‐en-­‐1-­‐ylmethyl)-­‐N,1-­‐
dimethylpiperidin-­‐4-­‐amine   2845571     
222.4   2.26  
6  
1-­‐[(E)-­‐3-­‐(2-­‐nitrophenyl)prop-­‐2-­‐
enyl]pyrrolidine   27267173  
  
232.3   2.95  
7  
4-­‐[(E)-­‐3-­‐(2-­‐nitrophenyl)prop-­‐2-­‐
enyl]thiomorpholine   783356  
  
264.3   3.03  
8   N-­‐(2-­‐piperidin-­‐1-­‐ylethyl)thiolan-­‐3-­‐amine   4107026  
  
214.4   1.81  
9   1-­‐[2-­‐(4-­‐chlorophenoxy)ethyl]piperidine   756651      239.7   4.26  
10   4-­‐[2-­‐(3-­‐chlorophenoxy)ethyl]morpholine   644756  
  
241.7   3.04  
11  
3,5-­‐dimethyl-­‐N-­‐(pyridin-­‐4-­‐
ylmethyl)aniline   791954  
  
212.3   2.59  
12   3,4-­‐dimethoxy-­‐N-­‐pyridin-­‐4-­‐ylbenzamide   814761  
  
258.3   1.74  
13  
N-­‐(pyridin-­‐4-­‐
ylmethyl)cyclohexanecarboxamide   823684  
  
218.3   1.48  
14  
2-­‐(2,4-­‐dioxo-­‐1,3-­‐thiazolidin-­‐5-­‐yl)-­‐N-­‐(2-­‐
hydroxyphenyl)acetamide   2905088  
  




carbothioamide   797068     
228.3   3.12  
16  
4-­‐[2-­‐(4-­‐nitropyrazol-­‐1-­‐
yl)ethyl]morpholine   2984635     







343.9   -­0.25  
18  
[2-­‐(2-­‐morpholin-­‐4-­‐
ylethoxy)phenyl]methanol;hydrochloride   45595395  
  
273.8   0.29  
19  
1-­‐[2-­‐(4-­‐iodo-­‐2-­‐methylphenoxy)ethyl]-­‐4-­‐
methylpiperazine;hydrochloride   6457337     
396.7   3.21  
20  
1-­‐[2-­‐[2-­‐(2,6-­‐dimethylmorpholin-­‐4-­‐
yl)ethoxy]phenyl]ethanone;hydrochloride   2996517     
313.8   1.5  
21  
5-­‐(2-­‐morpholin-­‐4-­‐ylethyl)-­‐1,3,4-­‐
thiadiazol-­‐2-­‐amine   3164058     
214.3   -­0.484  
22  
2-­‐(3-­‐methylpiperidin-­‐1-­‐yl)-­‐N-­‐(5-­‐methyl-­‐
1,3,4-­‐thiadiazol-­‐2-­‐yl)acetamide   3843682     
254.4   1.777  
23  
2-­‐(azepan-­‐1-­‐yl)-­‐N-­‐(1,3,4-­‐thiadiazol-­‐2-­‐
yl)acetamide   6469493     
240.3   1.434  
24  
N-­‐(2,5-­‐dichlorophenyl)-­‐2-­‐(3-­‐
methylpiperidin-­‐1-­‐yl)acetamide   4563532  
  
301.2   3.833  
25  
6-­‐chloro-­‐4-­‐N-­‐(pyridin-­‐3-­‐
ylmethyl)pyrimidine-­‐2,4-­‐diamine   14257470  
  
235.7   1.202  
26  
6-­‐chloro-­‐4-­‐N-­‐(2-­‐morpholin-­‐4-­‐
ylethyl)pyrimidine-­‐2,4-­‐diamine   45869411     
257.7   1.467  
27  
5-­‐[(4-­‐methoxyanilino)methyl]-­‐1,2-­‐
dihydro-­‐1,2,4-­‐triazol-­‐3-­‐one   45490304     





Figure B.1. Eukaryotic TOP2 structure, inhibition, and target 
selection. A) Eukaryotic TOP2 is composed of two functional subunits: 
the ATPase domain and the DNA cleavage domain. Here, the G-segment 
is bound in the DNA gate of TOP2, with the T-segment in position to 
enter through the N-gate. B) The binding of dexrazoxane functions to 
“lock” the N-gate, stabilizing the dimer interface in a closed position. C) A 
comparison of ScTOP2 and hTOP2A reveals a high degree of conservation 
in the dexrazoxane binding pocket, as visualized here using the PyMol 
color_by_conservation script. Red indicates well-conserved while blue 
indicates some divergence. D) OpenEyeTM make_receptor detects the 
shape of the binding pocket and gives a volume estimation. Here, the 








Figure B.2. Dexrazoxane inhibition of eukaryotic TOP2 ATPase 
activity. A) Raw 340 nm fluorescence readings for 2-fold titration series 
of dexrazoxane inhibiting hTOP2A. B) Slopes from linear regression of 
raw data analyzed to establish in vitro IC50 against hTOP2A. C) As in (A), 
but for ScTOP2. D) As in (B), but for ScTOP2. 
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Figure B.3. VLS compound inhibition of hTOP2A ATPase activity. 
340 nm fluorescence readings for NADH-coupled ATPase assays in the 
presence of 0, 5, and 50 µM of (A) Compound 6, (B) Compound 9, (C) 






Program 1: vina_library.sh 
#!/bin/bash -x 
 
#  vina_library.sh 
#  A script to run vina on a large library. Takes in the ligand 
root directory 
# 
#  Created by Alexia Miller on 2/13/15. 
# 
 
# User must specify a ligand directory 
if [ "$1" != "" ]; then 
    ligDir="$1" 
else 
    echo "Please specify a ligand directory!" 
    exit 1 
fi 
 










# Take out trailing slash in ligDir 




# For all the ligands (pdbqt files) in this directory 
for f in ${ligDir}/*.pdbqt; do 
    # b is the ligand name without the file extension 
    b=`basename $f .pdbqt` 
    # Reports what ligand we're working on 
    echo "Processing ligand $b" 
    vina --config conf.txt --ligand $f --out 









#  vina_to_pdb.sh 
#  A script to convert vina hits to pdb files and copy them to a 
#  tophits folder with rank indicated in the new filename 
# 
#  Created by Alexia Miller on 3/24/15. 
# 
 
# User must specify the filename for the Vina hits 
echo "Please specify the filename containing the output of 
vina_screen_get_top.py. Then press [ENTER]." 
read inFile 
 
# If nothing is entered, then exit the program 
if [ -z "$inFile" ]; then 
    echo -n "No filename specified." 
    exit 1 
fi 
 





# Remove first line from file 




# Translate spaces to returns in the file 
for i in `tr ' ' '\n' <temp_top.txt`; do 
    # isolate original directory 
    allHitsDir="${i%/*}" 
    # filename without directory or extension 
    hitname=`basename $i .pdbqt` 
    # make new name with hit number 
    rankname="${hitname}_rank${rank}" 
    # convert to pdb and move to tophits directory 
    obabel -ipdbqt $i -opdb -O "tophits/${rankname}.pdb" 
    # index the rank 






Program 3: myLabs.m 
 
function myLabs=concRanges(myConcs,iD) 
%% Concentration manipulations 
% Finding a nice concentration range for plotting 
if myConcs(1)<10^-3 
    myConcLab=myConcs*10^6; 
    concRange='µM'; 
elseif myConcs(1)<1 
    myConcLab=myConcs*10^3; 
    concRange='mM'; 
else 
    myConcLab=myConcs; 
    concRange='M'; 
end 
% Concentration labels 




Program 4: varAssign.m 
 
% A function that parses the atpase assay output from Clariostar 
% For use with nadhCSV, plotATPCSV, and getSlopes 
function 
[myData,timePts]=varAssign(dirName,fileName,rowOff,timeStep,myInd) 
%% Variable assignment 
% Finding the number of data columns (the number of reads) 
delimiter = ','; 
fid = fopen([dirName fileName],'rt'); 
i=1; 
while i<=rowOff+1 
    tLines = fgetl(fid); 
    i=i+1; 
end 
numCols = numel(strfind(tLines,delimiter)); 
fclose(fid); 
  
% Reading in sampleID number and raw absorbance values from the csv 
file 
fid=fopen([dirName fileName]); 
allData=textscan(fid,['%*s %*s Sample X%d',repmat('%f',[1,numCols-
3])],... 
    'CollectOutput',1','HeaderLines',rowOff,'Delimiter',','); 
fclose(fid); 
% All of the sample ID numbers 
unsortedID=allData{:,1}; 
% All of the data for each sample 
unsortedRaw=allData{:,2}; 
  
% Sorting the data based on the ID number 
[~,IX] = sort(unsortedID); 
rawData = unsortedRaw(IX,:); 
  
% Assigning the data appropriately 
myData=rawData(myInd,:); 
  







Program 5: nadhCSV.m 
 
% This is a function which reads in a csv file with the results of a 
% coupled atpase assay and returns the NADH standard curves 
% dirName=path to the directory containing your file; 
% fileName=csv results file name; 
% rowOff=row offset (after all the header lines); 
% timeStep=time in seconds between each plate read 
% nInd=indices of the NADH standards 





%% Variable assignment 
[nData,timePts]=varAssign(dirName,fileName,rowOff,timeStep,nInd); 
  
%% Concentration manipulations 
% If no concentration is given, this is the default (top is 200 µM) 
if isempty(nConcs) 
    nConcs=[200,100,50,0]*10^-6; 
end 
  
% Determining if concentrations are low-high and then reversing to 
high-low 
if nData(1,1)<nData(end,1) 
    nConcs=wrev(nConcs); 
end 
  
% Labels for plots including the appropriate concentrations 
nLabs=concRanges(nConcs,'NADH'); 
  
%% NADH Raw Data 
% New figure, hfig is the "handle" for this figure 
hfig=figure; 
% Plotting raw data for the NADH titration 
plot(timePts,nData','LineWidth',3) 
% Plot labels 
legend(nLabs) 
title('NADH Raw Data') 
xlabel('Time (s)') 
ylabel('340 nm Absorbance') 
% Plot style 
set(gca,'FontSize',16) 
set(gca, 'FontName', 'Helvetica') 
set(gca, 'Box', 'off', 'TickDir', 'out', 'TickLength', [.02 .02], ... 
    'XMinorTick', 'on', 'YMinorTick', 'on','LineWidth',2) 
  
% Filename includes directory and name of figure 
filename=[dirName saveID '_raw_data.png']; 
% Saving the image 
print(hfig,'-dpng','-r300',filename) 
  
%% NADH Standard calculations 
% Calculating average absorbances - just averages the whole curve 
nMeanAbs=mean(nData,2); 
 147 
% Fitting a linear curve to the four absorbances 
nLM=fitlm(nConcs,nMeanAbs); 
% Extracting the slope from the fit 
nSlope=nLM.Coefficients.Estimate(2); 
% Extracting the intercept from the fit 
nIntcpt=nLM.Coefficients.Estimate(1); 
  
% New figure 
hfig=figure; 
% Plotting the average absorbances 
scatter(nConcs,nMeanAbs,200,'filled') 
hold on 






% Plot labels 
title('NADH Standard Curve') 
xlabel('NADH Concentration (M)') 
ylabel('Mean 340 nm Absorbance') 
% Plot style 
set(gca,'FontSize',16) 
set(gca, 'FontName', 'Helvetica') 
set(gca, 'Box', 'off', 'TickDir', 'out', 'TickLength', [.02 .02], ... 
    'XMinorTick', 'on', 'YMinorTick', 'on','LineWidth',2) 
  
% Filename includes directory and name of figure 
filename=[dirName saveID '_standard_curve.png']; 







Program 6: plotATPCSV.m 
 
% A program that plots the data from an atpase assay 




%% Variable assignment 
[myData,timePts]=varAssign(dirName,fileName,rowOff,timeStep,myInd); 
  
%% Concentration manipulations 
myLabs=concRanges(myConcs,saveID); 
  
%% Converting and plotting raw data 
  
% Converting from absorbance to NADH concentration 
dataNorm=(myData-nIntcpt)./nSlope; 
  
% Defining colors for the graph 
ColorSet = varycolor(length(myInd)); 
% hfig is the figure handle for a new figure 
hfig=figure; 
hold on 
% For all the samples, plot on the same figure by using a for loop 
for i=1:length(myInd) 
    % Plot all the raw data with different colored lines 
    plot(timePts, dataNorm(i,:)','Color',ColorSet(i,:),'LineWidth',3) 
    %scatter(timePts, 
dataNorm(i,:)',75,'Marker','s','MarkerFaceColor',... 
    %    ColorSet(i,:),'MarkerEdgeColor',ColorSet(i,:)) 
end 
hold off 
% Plot labels 
legend(myLabs) 
title([saveID ' Raw Data']) 
xlabel('Time (s)') 
ylabel('NADH Concentration (M)') 
% Plot style settings 
set(gca,'FontSize',16) 
set(gca, 'FontName', 'Helvetica') 
set(gca, 'Box', 'off', 'TickDir', 'out', 'TickLength', [.02 .02], ... 
    'XMinorTick', 'on', 'YMinorTick', 'on','LineWidth',2) 
  
% Filename includes directory and name of figure 
filename=[dirName dataID '_raw.png']; 







Program 7: getSlopes.m 
 
% plots as in plotATPCSV.m, but then allows user to select linear 
regions of each plot 




%% Variable assignment 
[myData,timePts]=varAssign(dirName,fileName,rowOff,timeStep,myInd); 
  
%% Concentration manipulations 
myLabs=concRanges(myConcs,iD); 
  
%% Converting and plotting raw data 
% Converting from absorpance to NADH concentration 
dataNorm=(myData-nIntcpt)./nSlope; 
  
% Defining colors for the graph 
ColorSet = varycolor(length(myInd)); 
  
% Defining the linear regions of each curve 
for i=1:length(myInd) 
    figure 
    plot(timePts, dataNorm(i,:)','Color',ColorSet(i,:)) 
    selPts=selectdata('selectionmode','rect'); 
    begPts(i)=selPts(1); 








    plot(timePts, dataNorm(i,:)','Color',ColorSet(i,:),'LineWidth',3) 
end 
  
% Plot labels 
legend(myLabs) 
title([iD ' Raw Data']) 
xlabel('Time (s)') 
ylabel('NADH Concentration (M)') 
% Plot style 
set(gca,'FontSize',16) 
set(gca, 'FontName', 'Helvetica') 
set(gca, 'Box', 'off', 'TickDir', 'out', 'TickLength', [.02 .02], ... 
    'XMinorTick', 'on', 'YMinorTick', 'on','LineWidth',2) 
  
% Filename includes directory and name of figure 
filename=[dirName dataName '_unfitted.png']; 
% Saving the image 
print(hfig,'-dpng','-r300',filename) 
  
%% Fitting to the linear regions and plotting the fit 
for i=1:length(myInd) 
 150 
    
dataLM=fitlm(timePts(begPts(i):endPts(i)),dataNorm(i,begPts(i):endPts(i
))); 
    dataIntcpts(i)=dataLM.Coefficients.Estimate(1); 
    dataSlopes(i)=dataLM.Coefficients.Estimate(2); 
    dataLine=dataIntcpts(i)+dataSlopes(i)*timePts(begPts(i):endPts(i)); 
    
plot(timePts(begPts(i):endPts(i)),dataLine,'Color','k','LineStyle',... 
        '--','LineWidth',3) 
end 
legend(myLabs) 
title([iD ' Linear Fitted Data']) 
xlabel('Time (s)') 
ylabel('NADH Concentration (M)') 
  
set(gca,'FontSize',16) 
set(gca, 'FontName', 'Helvetica') 
set(gca, 'Box', 'off', 'TickDir', 'out', 'TickLength', [.02 .02], ... 
    'XMinorTick', 'on', 'YMinorTick', 'on','LineWidth',2) 
hold off 
  
% Filename includes directory and name of figure 
filename=[dirName dataName '_fitted.png']; 








title([iD ' Titration']) 
xlabel([iD ' Concentration (M)']) 




set(gca, 'FontName', 'Helvetica') 
set(gca, 'Box', 'off', 'TickDir', 'out', 'TickLength', [.02 .02], ... 
    'XMinorTick', 'on', 'YMinorTick', 'on','LineWidth',2) 
  
% Reference line for a 0 drug control 
if sum(myConcs==0)>0 
    ind=find(myConcs==0,1); 
    xl=xlim; 
    plot(xl,[-1*dataSlopes(ind) -1*dataSlopes(ind)],'LineWidth',3,... 





% Filename includes directory and name of figure 
filename=[dirName dataName '_slopes.png']; 





Program 8: doseResponseATPase.m 
NOTE: This function is essentially the doseResponse function [185] with 




Copyright (c) 2011, Ritchie Smith 
All rights reserved. 
 
Redistribution and use in source and binary forms, with or without modification, are 
permitted provided that the following conditions are met: 
 
    * Redistributions of source code must retain the above copyright notice, this list of 
conditions and the following disclaimer. 
    * Redistributions in binary form must reproduce the above copyright notice, this list 
of conditions and the following disclaimer in the documentation and/or other materials 
provided with the distribution 
 
THIS SOFTWARE IS PROVIDED BY THE COPYRIGHT HOLDERS AND CONTRIBUTORS "AS IS" AND ANY 
EXPRESS OR IMPLIED WARRANTIES, INCLUDING, BUT NOT LIMITED TO, THE IMPLIED WARRANTIES OF 
MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE ARE DISCLAIMED. IN NO EVENT SHALL 
THE COPYRIGHT OWNER OR CONTRIBUTORS BE LIABLE FOR ANY DIRECT, INDIRECT, INCIDENTAL, 
SPECIAL, EXEMPLARY, OR CONSEQUENTIAL DAMAGES (INCLUDING, BUT NOT LIMITED TO, PROCUREMENT 
OF SUBSTITUTE GOODS OR SERVICES; LOSS OF USE, DATA, OR PROFITS; OR BUSINESS INTERRUPTION) 
HOWEVER CAUSED AND ON ANY THEORY OF LIABILITY, WHETHER IN CONTRACT, STRICT LIABILITY, OR 
TORT (INCLUDING NEGLIGENCE OR OTHERWISE) ARISING IN ANY WAY OUT OF THE USE OF THIS 






% DOSERESPONSE     Computes the Hill Coefficient and EC50 of a 
% myConcs/mySlopes relationship given two vectors describing the 
myConcss and 
% mySlopess. A semilog graph is plotted illustrating the relationship, 
upon 
% which the man and standard error of the mySlopes to each myConcs 
level is 
% plotted along with the fitted Hill Equation sigmoid. The EC50 is also 
% labelled. Requires nlinfit from statistics toolbox. 
% 
%   Example 
%       d=[3.75 3.75 3.75 3.75 3.75 7.5 7.5 7.5 7.5 15 15 15 15 15 60 
60 60 60] 
%       r=[107 91 99 124 100 96 92 133 119 84 66 86 106 91 52 37 10 69] 
%       [hill ic50]=myConcsResponse(d,r) 
% 
%   Inputs 
%       Two vectors of the same length, the first containing the 
myConcs and 
%       the second the mySlopes. If myConcss of 0 are contained in the 
data, 
%       these are used as control values and the data are normalised by 
%       their mean value. 
% 
%   Notes 
%       This function was written to rapidly produce simple 
myConcs/mySlopes curves 
%       and EC50s for publication. 
 152 
  
%deal with 0 dosage by using it to normalise the results. 
normalised=0; 
if (sum(myConcs(:)==0)>0) 
    %compute mean control mySlopes 
    controlResponse=mean(mySlopes(myConcs==0)); 
    %remove controls from myConcs/mySlopes curve 
    mySlopes=mySlopes(myConcs~=0)/controlResponse; 
    myConcs=myConcs(myConcs~=0); 
    normalised=1; 
end 
  
%hill equation sigmoid 
sigmoid=@(beta,x)beta(1)+(beta(2)-beta(1))./(1+(x/beta(3)).^beta(4)); 
  














%plot the fitted sigmoid 
hfig=figure; 
xpoints=logspace(log10(minDose),log10(maxDose),1000); 
semilogx(xpoints,sigmoid(coeffs,xpoints),'Color',[0 0 0],'LineWidth',2) 
hold on 
  
%notate the IC50 
text(ic50,mean([coeffs(1) coeffs(2)]),[' \leftarrow ' 
sprintf('IC_{50}=%0.2g',ic50)],'FontSize',16); 
  





    mySlopess=mySlopes(myConcs==myConcss(i)); 
    meanResponse(i)=mean(mySlopess); 
    stdErrResponse(i)=std(mySlopess)/sqrt(length(mySlopess)); 






% Label plot 




    ylabel('Normalised ATPase Activity','FontSize',16); 
else 
    ylabel('ATPase Activity (M ATP/s)','FontSize',16); 
end 
set(gca,'FontSize',16); 
set(gca, 'FontName', 'Helvetica') 
set(gca, 'Box', 'off', 'TickDir', 'out', 'TickLength', [.02 .02], ... 
    'XMinorTick', 'on', 'YMinorTick', 'on','LineWidth',2) 
  
% Filename includes directory and name of figure 
filename=[dirName saveID '_ic50.png']; 






Program 9: coupledATPaseAnalysisTemplate.m 
 
%% Experimental data location and details 
% The directory where you have put your csv file 
dirName='~/Documents/BoschLab/Berger/Data/ATPase/15-09-
18_dexrazoxane/'; 
% The name of your csv file 
fileName='15-09-18_ScTopoII_ATPase_dex_control.txt'; 
% This is the time in seconds between each read 
% In this example, reads were taken every 20 seconds 
timeStep=20; 
  
%% NADH standard calculations 
% The sample IDs corresponding to your NADH titration 
% In this example, the first four samples were the NADH titration 
nInd=1:4; 
  
% The NADH concentrations of your titration. Concentrations are in M! 
% In this example, the concentrations are 200, 100, 50, and 0 
micromolar 
nConcs=[200 100 50 0]*10^-6; 
  
% The number of header rows (usually 7) 
rowOff=7; 
% Prefix for saving the output images 
saveID='NADH'; 
  
% The outputs of this function are the results of fitting the NADH 
standard 




%% Plotting data for a titration series 
% The sample IDs corresponding to the samples you would like to plot 
% In this example, the 5th through 12th samples are the ones to plot 
myInd=5:12; 
% These are the concentrations of the samples you want to plot (in M) 
% In this example, I have a dilution series ranging from 100 to 0 
micromolar 
myConcs=[100 50 25 12.5 6.25 3.125 1.5625 0]*10^-6; 
  
% % Another way to calculate a dilution series 
% % The high concentration is 100 micromolar 
% highConc=100*10^-6; 




% dilutSeries=[twoFolds inf]; 
% myConcs=highConc./dilutSeries; 
  
% This is the name of the drug/ATP/DNA/enzyme that you are titrating. 
It 
% will be used in the title and figure legend 
% In this example, I am titrating dexrazoxane 
 155 
dataID='Dexrazoxane'; 
% Prefix for saving output images 
saveID2='Dex'; 
  
% This will produce a nice plot labeled appropriately 
plotATPCSV(dirName,fileName,rowOff,saveID2,timeStep,myInd,myConcs,nSlop
e,nIntcpt,dataID) 
%% Getting slopes 






%% Plotting IC50 
% If you have performed a drug titration, this function will output the 
% IC50 and the Hill coefficient for that titration. 
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